Document:

Exhibit 10.7

 

Execution Copy

 

SUBSCRIPTION AGREEMENT

 

THIS SUBSCRIPTION AGREEMENT (this “Agreement”)
is made as of the 6th day of August 2013, by and among, Intec Pharma Ltd., a company organized under the laws
of the State of Israel (the “Company”) and each of the parties set out in Schedule A to this Agreement
(each – a “Subscriber” and collectively, the “Subscribers”). The Company and the Subscriber(s)
are referred to collectively as the “Parties” and each as a “Party”.

 

W I T N E S S E T H:

 

WHEREAS, the Company is
a public company organized under the laws of the State of Israel registered under number 513022780, whose securities are registered
for trading on the Tel Aviv Stock Exchange (the “TASE”);

 

WHEREAS, the Company has
an authorized share capital of NIS 4,000,000 divided into 400,000,000 Ordinary Shares of NIS 0.01 each (“Ordinary Shares”),
211,465,322 of which Ordinary Shares have been issued and are fully paid;

 

WHEREAS, the Company has
issued such number of options that are convertible into such number Ordinary Shares of the Company as are set out in Section 9(f)
below and Exhibit 9(f) (capitalization table) hereto;

 

WHEREAS, the Board of
Directors of the Company has determined that it is in the best interests of the Company to raise equity financing, all on the terms
and conditions more fully set out in this Agreement; and

 

WHEREAS, each of the Subscribers
wishes to invest in the Company for the price, and all upon and subject to the terms and conditions hereinafter contained.

 

NOW, THEREFORE,
in consideration of the mutual promises and covenants set forth herein, the Parties hereby agree as follows:

 

1.     Issue
and Allotment of Shares and Warrants. 

 

1.1      Subject
to the terms and conditions hereof, upon the Closing the Company shall issue and allot to the Subscribers respectively and the
Subscribers respectively shall purchase from the Company such number of Ordinary Shares of the Company as determined in accordance
with Section 1.3 below (in respect of each such Subscriber respectively, the “Subscription Shares”) and such
number of warrants to purchase Ordinary Shares as determined in accordance with Section 3 below (in respect of each such Subscriber
respectively, the “Warrants”), for the total price and upon and subject to the terms and conditions hereinafter
contained, free and clear from any mortgages, charges, pledges, liens and encumbrances whatsoever, save for any lock-up period
imposed by law or any other restriction that may be imposed by the Israel Securities Authority ("ISA").

 

    	- 1 -

    	 

    

 

1.2      In
consideration for the issue and allotment by the Company of the Subscription Shares and the Warrants to the Subscribers respectively,
the Subscribers respectively shall pay to the Company such total sum as set out respectively in Schedule A hereto opposite
such Subscriber’s name (in respect of each such Subscriber respectively, the “Subscription Price”),
which shall be in the aggregate of at least Two Million Five Hundred Thousand United States Dollars (US$2,500,000) and not exceeding
Four Million United States Dollars (US$4,000,000). Payments of the Subscription Price shall be made in New Israeli Shekels ("NIS")
or United States Dollars. If made in United States Dollars, conversion shall be calculated on the basis of the representative rate
of 3.577 New Israel Shekels against 1 United States Dollar.

 

1.3      The
total number of Subscription Shares to be sold by the Company to each Subscriber under this Agreement shall be determined and calculated
in accordance with the following formula:

 

$[Such Subscriber's Subscription Price]

PPS

 

Where:

 

PPS = NIS 1.1155

 

2.      Closing
of Sale and Purchase. 

 

2.1      Closing.
The closing in respect of all Subscribers, except Joinder Date Subscribers (as defined below) (the "Gabriel
Closing Date") shall occur on September 9, 2013 or such other date as mutually agreed upon by the Company and
Gabriel Capital (as defined below); provided, that the Gabriel Closing Date shall not be earlier than three (3) business days
after the Company receives the approval of the TASE as provided in Section 5.4 below. In the case of the Joinder Date
Subscribers (as defined in Section 2.6 below) – the closing shall occur on September 30, 2013 ); provided, that the
Joinder Closing Date shall not be earlier than three (3) business days after the Company receives the applicable approval of
the TASE as provided in Section 5.4 below (the “Joinder Closing Date”). Subject to the closing conditions
provided in Sections 6 and 7 below, (A) each of the Subscribers shall pay and transfer to the Company the Subscription Price
attributable to such Subscriber and (B) the Company shall issue to the registration company of the Company (Mizrahi Tefahot
Registration Company Ltd.) (the “Registration Company”) all the registration documents needed in order to
deposit the Subscription Shares at each of the Subscribers securities bank account in Israel, respectively (each such closing
with regard to each subscriber shall be referred to as a “Closing” and the date on which such Closing is
completed, shall be referred to as “Closing Date”). To avoid doubt, each Subscriber's obligations
hereunder including the payment of the Subscription Price to the Company before or on the relevant Closing Date, is an
independent obligation not contingent upon the performance of the obligations of the other Subscribers, it being
understood and agreed that the Gabriel Closing Date shall not occur if the Subscribers do not invest a minimum of Two Million
Five Hundred Thousand United States Dollars (US$2,500,000) and that the Joinder Closing Date is conditioned upon the Closing
taking place on the Gabriel Closing Date.

 

    	- 2 -

    	 

    

 

If the closing conditions
are not fulfilled by the Gabriel Closing Date or the Joinder Closing Date, as the case may be, through no fault of the Subscribers,
then the Subscribers may, at their sole option, extend the relevant Closing Date by up to an additional thirty (30) days, such
option to be exercised by notice in writing signed by or on behalf of the Subscribers to the Company, and delivered to the Company,
by not later than the original relevant Closing Date. If the closing conditions are not fulfilled by the Gabriel Closing Date or
the Joinder Closing Date, as the case may be, through no fault of the Company, then the Company may, at its sole option, extend
the relevant Closing Date by up to an additional thirty (30) days, such option to be exercised by notice in writing signed by or
on behalf of the Company, and delivered to the Subscribers, by not later than the original relevant Closing Date.

 

2.2      Transactions
at each Closing. Upon each Closing Date, the following transactions shall occur, which transactions shall be deemed to
take place simultaneously and none of such transactions shall be deemed to have been completed or any document delivered until
all such transactions have been completed and all required documents delivered:

 

(a) Each Subscriber
shall pay its Subscription Price in NIS or United States Dollars to the Company by bank transfer to the following account or pursuant
to other payment instructions reasonably acceptable to such Subscriber provided by the Company to the Subscribers at least three
business days prior to the respective Closing Date:

 

Account Name: Intec Pharma Ltd

Account Number: 24690/09

Currency: NIS

Bank: Union Bank of Israel

Branch: 063 (main branch of Tel Aviv)

 

(b) The Company shall
transfer to the Registration Company, with a copy to the Subscribers participating in the relevant Closing, as authenticated by
the Company's lawyers, all the documents and information needed in order to deposit the Subscription Shares of the Subscribers
at their accounts in Israel, or with a trustee (if so determined by the ISA in its approval) respectively which details shall be
provided by each of the Subscribers to the Company prior or on the Closing Date;

 

(c) The Company shall
deliver and/or procure the delivery to the Subscribers participating in the relevant Closing of:

 

(i)     copies
of any and all notices filed or to be filed upon the signing hereof with the ISA and the TASE and immediately following the
Closing (if and as applicable), as required by law or regulations in relation to the transactions contemplated by this
Agreement, and (a) the approval of the TASE to the listing of the Subscription Shares on TASE, and (b) approval of the TASE,
to the listing of the Warrant Shares (as defined below) on TASE; and

 

    	- 3 -

    	 

    

 

(ii)       a
correct copy of the resolution of the Company’s Board of Directors approving of the execution, delivery and performance of
this Agreement, including (a) the issuance of the Subscription Shares, (b) the issuance of the Warrants and, subject to the exercise
of the applicable Warrant by such Subscriber, of the Warrant Shares, to such Subscriber and the reservation of Ordinary Shares
issuable upon the exercise of the Warrant, (c) the issuance of the Additional Warrants (as defined below), subject to the TASE's
approval, and, subject to the exercise of the applicable Additional Warrant by such Subscriber, of the Additional Warrant Shares,
to such Subscriber and the reservation of Ordinary Shares issuable upon the exercise of the Additional Warrant, and (d) the agreements
and transactions contemplated hereby.

 

(d) Gabriel Capital Management
Ltd. ("Gabriel Management") shall deliver to the Company prior to the Closing Date details of the allocation of
the number of Warrant Shares and Additional Warrant Shares underlying the Warrants and Additional Warrants respectively to be granted
and allocated as among the Subscribers, (except Company's Additional Subscribers (as defined below), as provided in Sections 3.1
and 4.1 below respectively.

 

2.3      Listing
of Subscription Shares for Trading and Lock-Up. As all shares issued by a public company in Israel must be deposited and
registered by a Registration Company, at the Closing the Company shall provide to the Registration Company all the documents and
information needed in order to deposit the Subscription Shares of the Subscribers at their accounts respectively (to be an account
with a member of the TASE) which details shall be provided by each of the Subscribers to the Company prior or on the Closing Date.
Each of the Subscribers hereby acknowledges that the Company accepts no responsibility for compliance with such Subscriber’s
lock-up period requirements. The Parties acknowledge and are aware that the Subscription Shares will be subject to restrictions
on transfer according to the Securities Law, 1968. An extract from section 15C of the Israeli Securities Law, which contains the
main provisions of said lock up restrictions, is provided in Schedule B hereto. Each of the Subscribers acknowledges that
the contents of Schedule B are provided for informational purposes only and do not purport to be a comprehensive statement
of the applicable law.

 

2.4      The
Company shall promptly use its best efforts to obtain prior to the Gabriel Closing Date the (a) approval to the listing of the
Subscription Shares on TASE, and (b) approval to the listing of the Warrant Shares on TASE.

 

2.5      Additional
Gabriel Closing Date Subscribers. Gabriel Capital Management (GP) Ltd ("Gabriel Capital") shall have the
exclusive right to include one or more additional Subscribers in an aggregate Subscription Price of up to the difference between
the aggregate Subscription Prices set forth on Schedule A on the date hereof and Four Million United States Dollars (US$ 4,000,000)
within twelve (12) days following the date hereof. Such additional Subscribers, if any, along with any additional Subscribers included
by the Company and Gabriel between the thirteenth (13th) and sixteenth (16th) day following the date hereof (as of the thirteenth
day, on a “first come first serve” basis), shall execute a joinder to this Agreement, in the form provided in Schedule
C hereto, by no later than August 22, 2013, pursuant to which such additional Subscribers shall become a party to this Agreement
and shall, from such time, be considered Subscribers for all intents and purposes under this Agreement, investing on the Gabriel
Closing Date.

 

    	- 4 -

    	 

    

 

2.6      Joinder
Closing Subscribers. In the event that additional Subscribers included by Gabriel Capital and/or the Company pursuant to
Section 2.5 do not undertake to invest an additional amount equal to the difference between the aggregate Subscription Prices set
forth on Schedule A on the date hereof and Four Million United States Dollars (US$ 4,000,000, then Gabriel Capital and the Company
shall have the right to include one or more additional Subscribers in an aggregate Subscription Price of up to the difference between
such amount and the total sum utilized under Section 2.5 above, prior to September 9, 2013 on a “first come first serve”
basis (each, an "Joinder Date Subscriber"). Each Joinder Date Subscriber, if any, shall execute a joinder to this
Agreement, in the form provided in Schedule C hereto, by no later than September 9, 2013, pursuant to which such Joinder
Date Subscriber shall become a party to this Agreement and shall, from such time, be considered a Subscriber for all intents and
purposes under this Agreement, investing on the Joinder Closing Date. Moreover, the Company shall have the discretion to increase
the total sum invested by Joinder Date Subscribers by up to One Million United States Dollars (US$ 1,000,000), so that the aggregate
Subscription Price reaches up to Five Million United States Dollars (US$ 5,000,000).

 

The Subscribers included by the Company pursuant
to Sections 2.5 and 2.6 are referred to herein as "Company's Additional Subscribers" and the Subscribers included
by Gabriel Capital pursuant to Sections 2.5 and 2.6 are referred to herein as “Gabriel Additional Subscribers”.

 

3.     Terms
of Warrant. 

 

3.1       (A)     The Company hereby undertakes to issue, effective as of its Closing, Warrants to purchase from the Company an aggregate number
of Ordinary Shares of the Company in an amount that is sixty percent (60%) of the aggregate number of Subscription Shares issued
to all of the Subscribers under this Agreement that shall be allocated between the Subscribers as determined in accordance with
Section 3.1(B) and (C) below respectively (in respect of each such Subscriber respectively, the “Warrant Shares”),
and for a price per share, in the case of each such Subscriber, as determined in accordance with Section 3.2 below (in respect
of each such Subscriber respectively, the “Exercise Price”). There shall be no fractional shares issued, and
in the event that the aforesaid calculations result in any fraction that is 0.50 and up, then it shall be rounded-up to the nearest
whole number.

 

The Company shall,
at the Closing, sign and deliver to the Subscribers, the form of Certificates of Warrants, which shall be in the form attached
hereto as Exhibit 3.1.

 

(B)       The
number of Warrant Shares underlying the Warrants to be granted and allocated among the Subscribers, (including Gabriel Additional
Subscribers, but excluding Company's Additional Subscribers), shall be as determined by Gabriel Management and notified in writing
to the Company by Gabriel Management on or prior to August 25, 2013, and which determination and allocation shall be binding upon
the Parties.

 

    	- 5 -

    	 

    

 

(C)       The
number of Warrant Shares underlying the Warrants to be granted and allocated among Company's Additional Subscribers, if any, shall
be, in respect of each such Subscriber, equal to an amount that is sixty per cent (60%) of the number of Subscription Shares issued
to such Subscriber under this Agreement.

 

3.2       The
Exercise Price per share of the Warrant Shares shall be NIS 1.2828, as may be reduced pursuant to Section 8.2(a) below provided,
however, that the number of Warrant Shares or the Exercise Price shall be proportionally adjusted for any Recapitalization
Event or Merger Event (as such terms are defined below) occurring after the date of this Agreement and prior to the Warrant Closing
Date as follows:

 

(i)     Adjustment
for Share Splits and Reverse Splits. In the event the Company at any time while any of the Warrants are outstanding shall subdivide
or combine its Ordinary Shares, the number of Ordinary Shares issuable upon exercise of a Subscriber's Warrant(s) shall be proportionately
increased or decreased, as the case may be, and, for the avoidance of any doubt, the Exercise Price per share shall be proportionally
adjusted.

 

For the avoidance of
doubt, it is hereby clarified that any share fractions that may result as of a Share Split or Reverse Split will be sold by the
Company at TASE, after accumulated to a reasonable amount to be sold at TASE, for a period of 30 days after the said adjustment.
The net consideration, after the deduction of any sale expenses, commissions and levies, shall be paid to the Subscribers within
fourteen (14) days as of the sale date as mentioned above. The Company will not issue checks in an amount less than NIS 30.

 

(ii)       Adjustment
for Dividends. If the Company, at any time while this Warrant, or any portion hereof, remains outstanding and unexpired (the
"Record Date"), shall distribute to the holders of Ordinary Shares a dividend, whether payable out
of earnings or surplus legally available for dividends or by way of return of capital, then, immediately prior to the Record Date
the Exercise Price shall be reduced by an amount equal to the NIS amount of the per-share distribution on the Record Date fixed
for the purpose of such distribution (the "Adjusted Exercise Price"), but under no circumstances shall the Adjusted
Exercise Price be lower than the face value of the Ordinary Shares.

 

It is hereby clarified
that in the event: (i) the Subscriber(s) possesses a withholding tax exemption (the "Exemption"), the Exercise
Price will be equal to the Adjusted Exercise Price; (ii) the Subscriber(s) does not possess an Exemption, the Exercise Price shall
be reduced by an amount equal to the NIS amount of the per-share distribution on the Record Date fixed for the purpose of such
distribution net of applicable tax.

 

    	- 6 -

    	 

    

 

The Company will notify
immediately prior to the trade opening on the ex-dividend date, by way of an immediate report published on TASE site, of the Adjusted
Exercise Price. For the avoidance of doubt, no change in the base price Ordinary Share will occur.

 

(iii)      Adjustment
for Bonus Shares. In the event the Company at any time while any of the Warrants are outstanding makes, or fixes a record date
for the determination of holders of shares entitled to receive bonus shares, the number of Warrant Shares exercisable upon exercise
of the Warrants then outstanding shall be adjusted such that it shall be increased by a number of Warrant Shares equal to the number
of shares that such Subscriber would have been entitled to receive in respect of the Warrant Shares for which the Warrants could
have been exercised immediately prior to the ex-bonus shares date. If any adjustments are made pursuant to this Section 3.2(iii)
the Subscribers will not be entitled to any Ordinary Share fractions.

 

The Company will notify
immediately prior to the trade opening on the ex-bonus shares date, by way of an immediate report published on TASE site, of the
adjustment ratio.

 

(iv)      Adjustment
for Rights Offering. In the event the Company at any time while any of the Warrants are outstanding makes, or fixes a record
date for the determination of holders of shares entitled to receive rights to purchase Ordinary Shares upon any rights offering
by the Company, the Exercise Price will not be adjusted, however, the number of Warrant Shares exercisable upon exercise of the
Warrants then outstanding shall be adjusted to the bonus component in the rights offering as being expressed by a fraction, the
numerator of which shall be the closing price of the Ordinary Shares as published by TASE on the last trading day immediately prior
to the ex-rights date and the denominator of which shall be the ex-rights base price per share as shall be published by TASE. If
any adjustments are made pursuant to this Section 3.2(iv) the Subscribers will not be entitled to any Ordinary Share fractions.

 

The Company will notify
immediately prior to the trade opening on the ex-rights date, by way of an immediate report published on TASE site, of the adjustment
ratio.

 

(v)       Adjustment
for Pro-Rata Distributions. In the event the Company, at any time while any of the Warrants are outstanding, distributes to
holders of Ordinary Shares as a dividend any asset other than cash or the Company's securities (in each case, “Distributed
Property”), then forty-five (45) days prior to the distribution of the Distributed Property, the Company shall issue
a notice to the holders of the Warrants. Provided that the holders of the Warrants did not exercise the Warrants within the said
forty-five (45) days period, such holders will not be entitled to receive the Distributed Property that such holders would have
been entitled to receive in respect of the Warrant Shares for which the Warrants could have been exercised immediately prior to
the record date of such distribution.

 

    	- 7 -

    	 

    

 

(vi)      Adjustment
for Pro-Rata Distributions in Company Liquidation. In the event a resolution for liquidation of the Company will be made, at
any time while any of the Warrants are outstanding, the Company shall publish an announcement in two daily widely distributed Hebrew
newspapers, to state, inter alia, that each holder of the Warrants will be considered as if he had exercised the Warrants
prior to the said resolution (without prior paying the Exercise Price) unless such holders of the Warrants will notify the Company
thirty (30) days as of the said publication that they waive his right to exercise the Warrants. Provided that a holder of the Warrants
did not notify the Company of the said waiver within the set time frame, then they will be entitled, pro-rata, to a dividend in
cash that such holders would have been entitled to receive in respect of the Warrant Shares for which the Warrants could have been
exercised immediately prior to the record date of such resolution for liquidation, deducting the Exercise Price of the said dividend,
if any.

 

(vii)     Adjustment
for Merger Event. In the event there shall be a Merger Event (as defined below) at any time while any of the Warrants are outstanding,
then, subject to paragraph (viii) below and as a part of such Merger Event, lawful provision shall be made so that Subscriber(s)
shall thereafter be entitled to receive, upon exercise of such Subscriber's Warrant(s), the number of Ordinary Shares or other
securities or property of the successor corporation resulting from such Merger Event that would have been issuable if such Subscriber
had exercised such Subscriber's Warrant(s) immediately prior to the Merger Event. In any such case, appropriate adjustment (as
determined in good faith by the Company's Board of Directors with respect to all outstanding options and warrants issued by the
Company) shall be made in the application of the provisions of the Warrant(s) with respect to the rights and interests of each
Subscriber after the Merger Event to the end that the provisions of the Subscribers' Warrants (including adjustments of the Exercise
Price and/or number of Ordinary Shares purchasable) shall be applicable in their entirety. Without limiting the foregoing and subject
to paragraph (viii) below, in connection with any Merger Event, upon the closing thereof, the successor or surviving entity shall
assume the obligations of the Subscribers' Warrants.

 

(viii)      For
the avoidance of any doubt, if determined by the Company's Board of Directors in good faith that: (a) the implementation of the
provisions of paragraph (vii) above may impose an undue burden on the Company in the execution of a Merger Event, or (b) if the
terms of such implementation are not acceptable to the Subscribers or the Company - then the Subscribers shall have the right to
execute a “cashless exercise” in respect of such outstanding Warrants and the provisions of Section 3.6 below shall
apply, and the Company shall ensure that adequate provision is made in the documents constituting the Merger Event and reasonable
notice provided to the Subscribers prior to the consummation of such Merger Event so that the Subscribers may implement the “cashless
exercise” and participate accordingly. Warrants not exercised under this provision or not otherwise exercised prior to the
consummation of the Merger Event, shall be void and null.

 

“Recapitalization
Event” means all that was provided in sub-sections (i), (ii), (iii), (iv), (v) and (vi) of this Section 3.2, as the case
may be, or any other recapitalization, reclassification or similar event resulting in a change of such Ordinary Shares into a different
number of shares of the same class or any other class or classes of shares.

 

    	- 8 -

    	 

    

 

“Merger Event”
means a merger or consolidation involving the Company in which the Company is not the surviving entity, or in which the outstanding
shares of the Company’s Ordinary Shares are otherwise converted into or exchanged for shares of capital of another entity.

 

All the adjustments provisions
stipulated in this Section 3.2 are subject to any changes or adjustments required to be made in such adjustment provisions for
the purpose of obtaining the TASE's Approval for the registration of the Warrant Shares.

 

3.3       Each
Subscriber’s Warrants can be exercised by such Subscriber, in its sole discretion, in whole or in part, at any time after
the Closing Date and prior to the expiration of four (4) years from the Gabriel Closing Date (the “Exercise Period”)
(and, if exercised in part, with the Company being obliged to issue replacement Warrant certificates for the balance of such Subscriber's
Warrants still outstanding), but excluding the record date for (a) bonus shares distribution, (b) rights issuance, (c) dividend
distribution, (d) stock split, (e) stock consolidation, or (f) capital reduction (each of the above “Corporate Event”).
In case that the “Ex-Date” for a Corporate Event shall occur before the record date for such Corporate Event, the Warrants
may not be exercised on the said “Ex-Date”.

 

For the purposes
of this Section 3.3 and Sections 3.4, 3.5 and 3.6, the term “Warrant Shares” shall be those Warrant Shares as
shall be the subject of the Exercise Notice.

 

3.4       Each
Subscriber may exercise its Warrant(s) by giving written notice to the Company, in the form attached hereto as Schedule D,
at any time during the Exercise Period (in the case of each such Subscriber, the “Exercise Notice”).

 

Unless otherwise
agreed by the parties, the closing of each such Subscriber’s Warrants shall occur no later than three (3) trading days after
the delivery of such Subscriber’s Exercise Notice (in the case of each such Subscriber, the “Warrant Closing
Date”), at which time such Subscriber shall pay its Exercise Price to the Company by bank transfer in NIS, as
provided in Section 2.2(a), and following such payment, the Company shall issue and allot its Warrant Shares and transfer to the
Registration Company all the documents and information needed in order to deposit the Warrant Shares of such Subscriber at its
account which details shall be provided by such Subscriber to the Company in the Exercise Notice.

 

3.5       The
Company represents and warrants to the Subscriber respectively as of the Closing Date and as of the Warrant Closing Date of each
Subscriber respectively, as follows:

 

(a)     Upon
exercise of its Warrant, its Warrant Shares will be, when paid for as provided in this Agreement, duly authorized, validly issued
and fully paid and shall be issued and allotted free and clear from any mortgages, charges, pledges, liens or encumbrances whatsoever,
subject to any lock-up requirements as prescribed by law and Section 2.3.

 

(b)     The
Company is authorized to and shall issue and allot the Warrant Shares on the terms and subject to the conditions set out in this
Agreement and has reserved and will continue to reserve until the termination of the Exercise Period, a sufficient amount of authorized
and unissued Ordinary Shares as shall be required upon exercise of the Warrants.

 

    	- 9 -

    	 

    

 

3.6      Cashless
Exercise. Notwithstanding the foregoing, in lieu of exercising a proportion of each of the Subscriber's Warrants as provided
above, in whole or in part, such Subscriber may elect to receive Ordinary Shares equal to the value of its Warrants so exercised
(or the portion thereof being canceled), by written notice of such election to the Company, at the principal office of the Company,
in which event, the Company shall issue to such Subscriber, for no additional consideration except for the payment of the par value
thereof or the minimum required by TASE at the time of exercise (currently NIS 0.10 per share), that number of Ordinary
Shares computed using the following formula:

 

	 	 	Y (A - B)
	X	=	—————
	 	 	A

 

X         equals the number
of Ordinary Shares to be issued to such Subscriber;

 

Y         equals the number
of Ordinary Shares which would otherwise have been purchasable under the portion of such Subscriber's Warrant being
exercised, at the time of exercise pursuant to this formula (or the portion thereof being canceled);

 

A         shall equal the
“Fair Value” of one share of the Company's Ordinary Shares. Fair Value shall mean in the event that such
Subscriber's Warrant is exercised in accordance with the above formula: the price per share equal to the average of the closing
sale prices for the Ordinary Shares of the Company as reported on the Tel-Aviv Stock Exchange or, should the Company’s shares
be traded only on a different stock exchange, such stock exchange, for a consecutive period of ten (10) trading days immediately
prior to the date of exercise (i.e. delivery of Exercise Notice); and

 

B         equals such Subscriber's
Exercise Price in effect at the time of exercise pursuant to this formula.

 

4.     Grant
of Additional Warrants. 

 

4.1      (A)
The Company undertakes to issue, subject to the satisfaction of the Additional Warrant Condition (defined below), effective as
of October 1, 2014, additional warrants to purchase from the Company an aggregate number of Ordinary Shares of the Company in an
amount that is twenty-five per cent (25%) of the aggregate number of Subscription Shares issued to all of the Subscribers under
this Agreement that shall be allocated between the Subscribers as determined in accordance with Section 4.1(B) and (C) below respectively
(in respect of each such Subscriber respectively, the “Additional Warrant(s)” and the “Additional Warrant
Shares”, as the case may be), and for a price per share, in the case of each such 

 

    	- 10 -

    	 

    

 

Subscriber, as determined in accordance
with Section 3.2 above, as may be reduced pursuant to Section 8.2(b) below (in respect of each such Subscriber respectively, the
“Second Exercise Price”). There shall be no fractional shares issued, and in the event that the aforesaid calculations
result in any fraction that is 0.50 and up, then it shall be rounded-up to the nearest whole number.

 

For the purposes
of this Section 4.1, the satisfaction of the “Additional Warrant Condition” shall mean the failure on the part of the
Company, for whatever reason whatsoever, to have effected and consummated by September 30, 2014: (i) an initial public offering
of the Company’s Ordinary Shares on the NASDAQ Stock Market in which it raised at least Twelve Million United States Dollars
(US$12,000,000) or (ii) a merger with a company traded on the NASDAQ Stock Market which immediately following the closure of such
merger held free and unencumbered cash and/or publically raised, prior to September 30, 2014, a cumulative amount of at least Twelve
Million United States Dollars (US$12,000,000) (in either case, the "Dual Listing").

 

Subject to the
satisfaction or the imminent satisfaction of the Additional Warrant Condition, the Company shall, prior to or on October 1, 2014,
sign and deliver to the Subscribers, the form of Certificates of Additional Warrants, in the form attached hereto as Exhibit
4.1.

 

(B)       The
number of Additional Warrant Shares underlying the Additional Warrants to be granted and allocated among the Subscribers, (including
Gabriel Additional Subscribers, but excluding Company's Additional Subscribers), shall be as determined by Gabriel Management and
notified in writing to the Company by Gabriel Management prior to the Closing Date and may be revised by Gabriel Management with
a written notice to be provided to the Company by no later than August 10, 2014, and which determination and allocation shall be
binding upon the Parties.

 

(C)       The
number of Additional Warrant Shares underlying the Additional Warrants to be granted and allocated among Company's Additional Subscribers,
if any, shall be, in respect of each such Subscriber, equal to an amount that is twenty-five per cent (25%) of the number of Subscription
Shares issued to such Subscriber under this Agreement.

 

4.2      The
number of Additional Warrant Shares or the Second Exercise Price shall be proportionally adjusted for any Recapitalization Event
or Merger Event (as such terms are defined above) occurring after the date of this Agreement and prior to the Additional Warrant
Closing Date in accordance with the provisions of Section 3.2 above, which provisions shall mutatis mutandis apply.

 

4.3      Each
Subscriber’s Additional Warrants can be exercised by such Subscriber, in its sole discretion, in whole or in part, at any
time after issuance and prior to September 30, 2016 (the “Second Exercise Period”) (and, if exercised in part,
with the Company being obliged to issue replacement Additional Warrant certificates for the balance of such Subscriber's Additional
Warrants still outstanding), but excluding the record date for a Corporate Event (as defined above). In case that the “Ex-Date”
for a Corporate Event shall occur before the record date for such Corporate Event, the Additional Warrants may not be exercised
on the said “Ex-Date”.

 

    	- 11 -

    	 

    

 

For the purposes of this
Section 4.3 and Sections 4.4, 4.5 and 4.6, the term “Additional Warrant Shares” shall be those Additional Warrant
Shares as shall be the subject of the Second Exercise Notice.

 

Should it become clear
or more probable than not that the Additional Warrant Condition will be met, the Company shall use its best efforts, as from September
1, 2014, to obtain within thirty (30) days thereafter the approval to the listing of the Additional Warrant Shares on TASE and
any other regulatory approvals as may be required. Should TASE or any other regulatory authority condition its approval to the
listing of the Additional Warrant Shares upon any change or adjustment to the provisions of Section 3.2 above, then the Chairman
of the Board of the Company and Gabriel Capital shall negotiate a solution, in good faith, that will give effect to the intent
of the parties. Should the Company and Gabriel Capital be unable to reach an agreed-upon solution within a five (5) day period,
an arbitrator will be appointed (if Gabriel Capital and the Company cannot agree on an arbitrator within 2 days) by the Chairman
of the Israeli Bar Association and the Parties agree that such arbitrator will provide the solution, which will be final and binding
upon the Parties, within five (5) days of his or her appointment It is understood and agreed that any change or adjustment to the
form of the Certificates of Warrants (Exhibit 3.1) that was agreed upon by Gabriel Capital pursuant to Section 6.4 below shall
be deemed as to have automatically amended the form of the Certificate of Additional Warrants (Exhibit 4.1) in an identical manner.

 

4.4      Each
Subscriber may exercise its Additional Warrant(s) by giving written notice to the Company, in the form attached hereto as Schedule
D, at any time during the Second Exercise Period (in the case of each such Subscriber, the “Second Exercise
Notice”).

 

Unless otherwise agreed
by the parties, the closing of each such Subscriber’s Additional Warrants shall occur no later than three (3) trading days
after the delivery of such Subscriber’s Second Exercise Notice (in the case of each such Subscriber, the “Additional
Warrant Closing Date”), at which time such Subscriber shall pay its Second Exercise Price to the Company by bank transfer
in NIS, as provided in Section 2.2(a), and following such payment, the Company shall issue and allot its Additional Warrant Shares
and transfer to the Registration Company all the documents and information needed in order to deposit the Additional Warrant Shares
of such Subscriber at its account which details shall be provided by such Subscriber to the Company in the Second Exercise Notice.
For the avoidance of any doubt, such Subscriber shall not be obliged pay its Second Exercise Price to the Company until the Company
shall deliver to it the approval to the listing of the Additional Warrant Shares on TASE.

 

4.5      The
Company represents and warrants to the Subscriber respectively as of the Closing Date and as of the Additional Warrant Closing
Date of each Subscriber respectively, as follows:

 

    	- 12 -

    	 

    

 

(a)     Upon
exercise of its Additional Warrant, its Additional Warrant Shares will be, when paid for as provided in this Agreement, duly authorized,
validly issued and fully paid and shall be issued and allotted free and clear from any mortgages, charges, pledges, liens or encumbrances
whatsoever, subject to any lock-up requirements as prescribed by law and Section 2.3.

 

(b)     The
Company is authorized to and shall issue and allot the Additional Warrant Shares on the terms and subject to the conditions set
out in this Agreement and has reserved and will continue to reserve until the termination of the Second Exercise Period, a sufficient
amount of authorized and unissued Ordinary Shares as shall be required upon exercise of the Additional Warrants.

 

4.6      Cashless
Exercise. Notwithstanding the foregoing, in lieu of exercising a proportion of each of the Subscriber's Additional Warrants
as provided above, in whole or in part, such Subscriber may elect to receive Ordinary Shares equal to the value of its Additional
Warrants so exercised (or the portion thereof being canceled), by written notice of such election to the Company, at the principal
office of the Company, in which event, the Company shall issue to such Subscriber, for no additional consideration except for the
payment of the par value thereof or, the minimum required by TASE at the time of exercise (currently NIS 0.10 per share),
that number of Ordinary Shares computed using the formula in accordance with the provisions of Section 3.6 above, which provisions
shall mutatis mutandis apply.

 

5.     On-Going
Reporting Obligations by the Subscribers. Each of the Subscribers shall, at all relevant times after the Closing,
if and when required by law or regulations, duly and properly file or provide notices and/or procure the filing of any and all
notices in relation to its purchases, sales and holdings in the Company as made or in existence from time to time.

 

6.     Conditions
of Closing of the Subscribers. The obligations of each of the Subscribers respectively to purchase their Subscription
Shares and to transfer the funds representing their Subscription Price to the Company at the Closing are contingent on and subject
to the fulfillment at or before the Closing of the following conditions precedent, any one or more of which may be waived in whole
or in part, with respect to each such Subscriber, which waiver shall be at the sole discretion of such Subscriber:

 

6.1       Representations
and Warranties. The representations and warranties made by the Company in this Agreement shall have been true and
correct in all material aspects when made, and shall be true and correct in all material aspects as of the Closing as if made on
the Closing Date.

 

6.2       Covenants.
All covenants, agreements, and conditions contained in this Agreement to be performed or complied with by the Company prior
to the Closing shall have been performed or complied with by the Company, prior to or at the Closing.

 

    	- 13 -

    	 

    

 

6.3      Proceedings
and Documents. All corporate and other proceedings in connection with the transactions contemplated at or prior to the
Closing, and all documents to be delivered by the Company incident thereto and pursuant to Section 2 shall be reasonably satisfactory
in form and substance to the Subscribers, and the Subscribers shall have received all such counterpart original and certified or
other copies of such documents as it may reasonably request.

 

6.4      TASE
Approval. The Company shall have received the TASE’s (a) approval to the listing of the Subscription Shares on TASE,
and (b) approval to the listing of the Warrant Shares on TASE, it being understood and agreed, however, that should TASE condition
its approvals to the listing of the Warrant Shares upon any change or adjustment to the provisions of Section 3.2 above, then such
change or adjustment shall be subject to Gabriel Capital's approval, in writing, in order for this Closing condition to be met.

 

6.5      Corporate
Approval. The Company shall have received all such corporate body approvals as necessary to enable it to enter into and
perform this Agreement and the Company shall have delivered to the Subscribers a letter from its attorneys to that effect.

 

7.     Conditions
of Closing of the Company. The obligations of the Company to issue and allot the Subscription Shares and to grant the Warrant(s)
and Additional Warrants) to each of the Subscribers respectively are contingent on and subject to the fulfillment at or before
the Closing of the following conditions precedent, any one or more of which may be waived in whole or in part by the Company, which
waiver shall be at the sole discretion of the Company:

 

7.1      Payment
of the Subscription Price. Such Subscriber shall have fully paid its Subscription Price, as and when due hereunder.

 

7.2      Proceedings
and Documents. All corporate and other proceedings in connection with the transactions contemplated at the Closing,
and all documents to be delivered by the Subscribers respectively incident thereto and pursuant to Section 2 shall be reasonably
satisfactory in form and substance, and the Company shall have received all such counterpart original and certified or other copies
of such documents as it may reasonably request.

 

7.3      TASE
Approval. The Company shall have received the TASE’s (a) approval to the listing of the Subscription Shares
on TASE, and (b) approval to the listing of the Warrant Shares on TASE.

 

7.4      Subscriber’s
Corporate Approval. Each of the Subscribers respectively shall have received all such corporate body approvals as
necessary to enable it to enter into and perform this Agreement.

 

7.5      Company’s
Corporate Approval. The Company shall have received all such corporate body approvals as necessary to enable it
to enter into and perform this Agreement.

 

7.6      Information
Regarding Subscribers. Each Subscriber shall have provided the Company with a declaration, to the extent required
by the TASE and/or ISA, regarding its identity, its place of incorporation, its line of business, its controlling shareholders
(up to the level of an individual), whether there is any collaboration to apply following the Closing, between itself and any other
Subscriber and/or any shareholder in the Company and the details of its bank account in Israel.

 

    	- 14 -

    	 

    

 

8.     Downside
Protection 

 

8.1      Until
immediately following the earlier of (the “Protection Period”): (i) the Dual Listing (as defined in Section
4.1), (ii) consummation of an “M&A Event” (as defined in Section 8.3), or (iii) the expiration of four (4)
years after the Closing - the Subscriber will be entitled to a downside protection as provided below.

 

In any case
of the occurrence of an M&A Event (as defined below) or an investment of new funds in the Company during the Protection Period
(including, for the avoidance of doubt, (A) any issuance of shares in or as part of a public offering or in connection therewith,
and (B) the transactions constituting the M&A Event), except for an Excluded Investment (as defined below), at a price per
share in respect of such issuance or underlying such M&A Event (“Downside Event” and the “Investment/Exit
Price Per Share” respectively) that is lower than NIS 1.3386 (the “Protection Threshold Price”),
then the number of Subscription Shares to which each of the Subscribers is entitled to under this Agreement shall be adjusted and
the total number of shares to be additionally issued to the Subscriber shall equal to and be calculated in accordance with the
following formula (the “Protection Formula”):

 

	(X-Z)* Y	-  V
	Z

 

Where:

 

X = the Protection Threshold Price.

Z = the Investment/Exit Price Per Share.

Y =
the number of Subscription Shares issued to each Subscriber upon the Closing minus Ordinary Shares sold by the Subscriber
following the Closing and until the Downside Event.

V =
the total number of shares additionally issued to such Subscriber under previous applications of this Section 8.1.

 

Should TASE or any other regulatory
authority condition its approval to the listing of such additional shares, the provisions of the third paragraph of Section 4.3
shall apply, mutatis mutandis.

 

8.2        In
the event of the application of Section 8.1:

 

(a)     the
Exercise Price for each of the Warrants, still held by a Subscriber as of the triggering of this Section 8.1, shall be reduced
by that percentage discount thereto as shall equal the same percentage discount that the Investment/Exit Price Per Share bears
to the Protection Threshold Price, provided that in the event of the application of Section 8.1 in a second or subsequent occurrence,
then, for the purposes of this paragraph (a), the "Protection Threshold Price" shall mean the Investment/Exit Price Per
Share as shall have been applicable in the previous application of Section 8.1; and

 

    	- 15 -

    	 

    

 

(b)     the
Second Exercise Price for each of the Additional Warrants, still held by a Subscriber as of the triggering of this Section 8.1,
shall be reduced by that percentage discount thereto as shall equal the same percentage discount that the Investment/Exit Price
Per Share bears to the Protection Threshold Price, provided that in the event of the application of Section 8.1 in a second or
subsequent occurrence, then, for the purposes of this paragraph (b), the "Protection Threshold Price" shall mean the
Investment/Exit Price Per Share as shall have been applicable in the previous applications of Section 8.1.

 

8.3      For
the purposes of this Section 8, the term “M&A Event” shall mean a transaction or a series of related transactions
which entails (i) the sale of all or substantially all of the Company's assets; (ii) the acquisition of the Company by, or the
merger of the Company with, another entity, consolidation, reorganization, recapitalization, sale, assignment or disposal by the
Company of all or substantially all of the shares of the Company (where the Company is not the surviving entity); and/or (iii)
any other transaction or series of related transactions in which the shareholders of the Company prior to the closing of such transaction
own, directly or indirectly, less than 50% (fifty percent) of the voting power of the Company or surviving entity.

 

8.4      For
the purposes of this Section 8, the term “Excluded Investment” shall mean: (i) the exercise of any options or warrants
outstanding as of the date hereof in accordance with their respective terms in effect as of the date hereof, and (ii) the exercise
of any options or warrants granted to employees, directors or service providers of the Company.

 

For the avoidance of any doubt,
the terms of this Section 8 shall also be adjusted for any Recapitalization Event or Merger Event as provided herein.

 

8.5      The provisions
of this Section 8 shall apply only if an aggregate amount of Two Million Five Hundred Thousand US Dollars (US$ 2,500,000) are invested
in the Company by the Subscribers (including Gabriel Additional Subscribers, but excluding Company's Additional Subscribers), at
the Closings pursuant to this Agreement.

 

9.     Representations
and Warranties of Company 

 

The Company
represents and warrants to each of the Subscribers as of the Gabriel Closing Date and the Joinder Closing Date, as the case may
be, as follows:

 

(a)     The
Subscription Shares will be, when paid for as provided in this Agreement and so issued, duly authorized, validly issued and fully
paid and shall be issued and allotted as provided herein free and clear from any mortgages, charges, pledges, liens or encumbrances
whatsoever, subject to any lock-up requirements as prescribed by law and Section 2.3. The representations set out in Sections
3.5 and 4.5 above, with regard to the Warrant Shares and Additional Warrant Shares, are true and correct.

 

    	- 16 -

    	 

    

 

(b)     The
Company is entitled to and shall issue and allot the Subscription Shares and grant the Warrants and Additional Warrants –
in each case, on the terms and subject to the conditions set out in this Agreement.

 

(c)     The
Company has taken all corporate and other actions necessary to enable it to enter into and perform this Agreement. The execution
and delivery of this Agreement by the Company does not, and the performance by the Company of its obligations under this Agreement,
will not, with or without the giving of notice or the lapse of time or both, (i) conflict with or violate the organizational documents
of the Company or any of its subsidiaries, (ii) violate any law, statute, ordinance, rule, regulation, order, judgment or decree
applicable to the Company or any of its subsidiaries or by which any of its respective properties or assets is bound or affected,
and (iii) conflict with or violate any license or contract or agreement or undertaking of the Company and/or any its subsidiaries
with any third party or governmental authority or provide third parties the right to amend or terminate any material agreements.
The Company is not in breach of any license or permit or material agreement and is not aware of any material issues that will prevent
extension or renewal of such licenses and permits.

 

(d)     The
Company has the capacity and authority to execute and deliver this Agreement, to perform hereunder and to consummate the transactions
contemplated hereby without the necessity of any further act or consent of, or the provision of any notice to, any other person
whomsoever, except as specifically provided herein. This Agreement and each and every other agreement, document and instrument
to be executed, delivered and performed by or on behalf of the Company pursuant hereto have been duly executed and delivered by
a duly authorised representative of the Company and constitutes or will, when executed and delivered, constitute the legal, valid
and binding obligations enforceable against the Company in accordance with its terms.

 

(e)     The
Company is a corporation duly organized and validly existing under the laws of the State of Israel. The Company is duly qualified
to conduct its business and has the requisite corporate power and authority and any necessary governmental authority, franchise,
license or permit to own, operate, lease and otherwise to hold and operate its assets and properties and to carry on its businesses
as now being conducted and as currently contemplated to be conducted. The Articles of Association of the Company as in effect as
of the date hereof are in the form as published by the Company's “Immediate Report” on “MAGNA” on June
6, 2012.

 

(f)     As
of the date hereof, the registered share capital of the Company is NIS 4,000,000, which registered share capital is divided into
400,000,000 Ordinary Shares of NIS 0.01 each, of which 211,465,322 are issued and outstanding. In addition, as of the date hereof,
the Company has issued (i) Series 1 Options (tradable) that are convertible into Ordinary Shares of the Company, (ii) Options (non-tradable)
that are convertible into Ordinary Shares of the Company, and (iii) options to employees, consultants and directors (non-tradable)
that are convertible into Ordinary Shares of the Company, as are set out in the capitalization table of the Company set out in
Exhibit 9(f) hereto, and which, for each of the options referred to in sub-paragraphs (i), (ii) and (iii) above,
details the total number of Ordinary Shares of the Company into which such options are convertible, their respective exercise prices
and expiry dates, provided that with respect to the options under sub-paragraph (iii) above, there shall be no requirement to detail
the exercise price or expiry date of each such option, but only the number of options, expressed in the aggregate.

 

    	- 17 -

    	 

    

 

None of the
options, warrants or other convertible securities outstanding as of the date hereof and the Closing Date shall have any price protection
or anti-dilution protection in accordance with their existing terms, other than adjustments in the nature of Recapitalization Events,
as provided to the Company's existing warrant holders.

 

(g)     The
Company is a public company whose securities are traded on the TASE. The Company is, and at all times has been, in all material
respects, in compliance with all applicable regulatory requirements in making all filings required, and complying with all filing
requirements stipulated by the Israeli Securities Law and the regulations promulgated thereunder (the “Filings”).
Without derogating from the generality of the above, each Filing (i) includes all required information under applicable law, and
(ii) does not include any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary in order to make statements therein, in light of the circumstances in which they were made, not misleading, except
to the extent such statements have been modified or superseded by later Filings filed and publicly available prior to the date
hereof.

 

(h)     From
the date of the Company's quarterly reports as of March 31, 2013, through the date of this Agreement and the Gabriel Closing Date,
the businesses of the Company and its subsidiaries have been conducted, in all material respects, in the ordinary course of business
consistent with past practice and there has not been any event, development or state of circumstances involving any of the following
and that has not been disclosed in an “Immediate Report” of the Company prior to the date hereof: (A) any event, development
or state of circumstances that has had, individually or in the aggregate, a Material Adverse Effect, (B) any material amendment
or modification of any material agreement or arrangement involving the Company, (C) any loans by the Company to its directors,
officers, employees or consultants and/or (D) any interested party transactions. “Material Adverse Effect“ means such
facts, circumstances, events, conditions, occurrences, actions, omissions or changes that, individually or in the aggregate, are
reasonably expected to (i) result in a materially adverse effect on or to the business, financial condition or results of operations
of the Company and its subsidiaries, taken as a whole or (ii) prevent, materially impede or materially delay the consummation by
the Company of the transactions contemplated by this Agreement.

 

(i)     Except
as expressly provided herein, no consent or authorization from any governmental authority, court or third party is required by
the Company for the execution or performance of this Agreement.

 

(j)     Except
as set out in the Filings: (A) no action, proceeding or governmental inquiry or investigation is pending or to the Company’s
knowledge threatened against the Company, or against any of the Company's properties, or with regard to the Company’s business,
before any court, arbitration board or tribunal or administrative or other governmental agency nor, to the Company’s knowledge,
is there any basis for the success of the foregoing, which action, proceeding or governmental inquiry or investigation will have
a material adverse effect on the Company; (B) the Company is not a party to or subject to the provisions of any order, writ, injunction,
judgment or decree of any court or governmental agency or instrumentality, and (C) there is no action, suit, proceeding or investigation
that the Company intends to initiate.

 

    	- 18 -

    	 

    

 

(k)     The
information provided by the Company to the Subscribers contains public information concerning the Company and does not include
any information that is or could be deemed to be "internal information", as such term is defined in the Israeli Securities
Law.

 

10. Representations and Warranties of each of the
Subscribers

 

Each of the
Subscribers respectively represents and warrants to the Company as of the date hereof and as of the Closing Date as follows:

 

10.1       Such
Subscriber has the capacity and authority to execute and deliver this Agreement, to perform hereunder and to consummate the transactions
contemplated hereby without the necessity of any further act or consent of any other person whomsoever.

 

10.2       Such
Subscriber has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks
relating to the acquisition of the shares in the Company.

 

10.3       Except
as set out in Section 9 and in the Company’s publically available reports to the TASE, such Subscriber acknowledges that
the Company has made no other representations and warranties to it. 

 

10.4       The
Subscribers acknowledge that they are familiar with the provisions of the Securities Law and the Securities Law Regulations (Details
with regard to Sections 15A to 15C of the Law), 2000, and are committed to act in accordance with such provisions, regarding the
restrictions in reselling of the Subscription Shares, the Warrant Shares and the Additional Warrant Shares.

 

10.5       The
Subscribers acknowledge that the Company is obliged to publicize in an immediate notice to the TASE following the Closing, which
shall contain, inter alia, details of their investment in the Company, their line of business and their controlling shareholders
(up to the level of an individual), provided that any such notice shall be made after consulting with and receiving the approval
of Gabriel Capital. Nothing in the foregoing shall be construed as restricting the Company from complying with applicable law.

 

    	- 19 -

    	 

    

 

11.       Registration
Rights 

 

The Company agrees and
undertakes that it shall register and include the Subscription Shares, the Warrant Shares and Additional Warrant Shares that may
be issued upon the exercise of the Warrants in its registration statement on Form F-1, F-3, or any comparable document, which is
the Company's first registration statement filed with the US Securities and Exchange Commission in connection with the initial
public offering of the Company's shares in the United States, and shall use commercially reasonable efforts to keep such registration
statement continuously effective under the US Securities Act of 1933 (as amended, the “Securities Act”) until
all securities covered by such registration statement have been sold, or may be sold without restrictions pursuant to Rule 144
or any other exemption from registration promulgated under the Securities Act. If such registered offering of the Company's shares
is underwritten and the underwriter of such registered offering determines, or, if such registered offering of the Company's shares
is not underwritten, the Company's board of directors determines, that marketing factors require a limitation of the number of
Subscription Shares, Warrant Shares and Additional Warrant Shares to be underwritten or registered, as applicable, in such registered
offering, then, the number of Subscription Shares, Warrant Shares and Additional Warrant Shares that may be included in the underwriting
or other registration shall be reduced to such amount determined by the underwriters or the Company's board of directors as applicable,
to be allocated first to the Company and then to the Subscribers, and the Subscribers shall receive, at Company's cost, customary
demand registration rights with respect to the Shares, Warrant Shares and Additional Warrant Shares excluded from such registration
statement. The Company further agrees that it shall not register the securities of any other shareholders of the Company in a registration
statement prior to the registration of the Subscription Shares, Warrant Shares and Additional Warrant Shares as provided above.
Each Subscriber hereby agrees to sign customary lock up agreements as may be requested by the underwriter of the Company's securities
in the United States.

 

12. Legal Fees and Expenses.
It is acknowledged and agreed that the Company shall pay to Gabriel Management upon the Gabriel Closing Date the sum of US$30,000
plus VAT, being part of the Subscribers' fees of and incidental to the preparation of this Agreement and the transactions contemplated
hereunder. In all other respects, each of parties shall bear and pay its costs and disbursements of and incidental to the preparation
of this Agreement and the transactions contemplated hereunder.

 

13. Miscellaneous

 

13.1       Termination.
It is hereby acknowledged and agreed that each Subscriber shall be under no obligation to make payment of Subscription
Price unless and until all the conditions set out in Section 6 above have been satisfied and/or waived by Gabriel Capital, at its
sole discretion. In the event that the Gabriel Closing Date has not taken place by September 9, 2013 or such longer period as provided
herein or as mutually agreed upon by the Company and Gabriel Capital, then this Agreement shall automatically terminate, and neither
Party shall thereafter have any rights against the other arising hereunder, except in respect of any breach by a Party hereunder
arising prior thereto.

 

13.2       Successors
and Assigns; Assignment. Except as otherwise expressly limited herein, the provisions hereof shall inure to the
benefit of, and be binding upon, the transferees, successors, assigns, heirs, executors, and administrators of the parties hereto.

 

    	- 20 -

    	 

    

 

13.3       Further
Assurances. Each of the parties hereto shall perform such further acts and execute and deliver such further documents as
may reasonably be necessary to carry out and give full effect to the provisions of this Agreement and the intentions of the parties
as reflected thereby.

 

13.4       Governing
Law; Jurisdiction. This Agreement shall be governed by and construed according to the laws of the State of Israel, without
regard to the conflict of laws provisions thereof. Any dispute arising under or in relation to this Agreement shall be resolved
in the competent court for Tel Aviv-Jaffa district, and each of the parties hereby submits irrevocably to the jurisdiction of such
court.

 

13.5       Entire
Agreement; Amendment and Waiver. This Agreement and the Schedules attached hereto constitute the full and entire understanding
and agreement between the parties with regard to the subject matters hereof and thereof. The Company makes and has given no other
warranties or representations, other than as expressly contained herein. Any term of this Agreement may be amended and the observance
of any term hereof may be waived (either prospectively or retroactively and either generally or in a particular instance), including,
without limitation, with regard to any term of Section 8 (Downside Protection) only with the written consent of the Company and
Gabriel Capital. The recitals hereto constitute an integral part of this Agreement.

 

By signing this Agreement,
each of the Subscribers hereby acknowledge and agree that any term of this Agreement as shall be amended and/or waived in the manner
provided above shall be final and binding on each of Subscribers and the Company, and none of the Subscribers shall have any right
or claim against the Company or Gabriel Capital and/or its directors, shareholders, partners, representatives and/or affiliates
for any loss or damages caused by, directly or indirectly, and/or arising from or referable to, such amendment and/or waiver of
any term of this Agreement.

 

13.6       Notices.
 All notices and other communications required or permitted hereunder to be given to a party to this Agreement shall be in writing
and shall be telecopied or mailed by registered or certified mail, postage prepaid, or otherwise delivered by hand or by messenger,
addressed to such party's address as set forth below or at such other address as the party shall have furnished to each other party
in writing in accordance with this provision:

 

	         if to the Company:	Intec Pharma Ltd.
	 	12 Hartum St. Jerusalem, Israel
	 	Facsimile: +972-77-4710797
	 	Attention: Nir Sassi, CFO
	 	 
	         with a copy to:	Pearl Cohen Zedek Latzer Baratz
	 	Facsimile: 03-6073778
	 	Attention:  Yael Baratz, Adv.
	 	 
	          if to the Subscribers:  as set out in Schedule A hereto.

 

    	- 21 -

    	 

    

 

	           with a copy to:	Ephraim Abramson & Co.
	 	Beit Hatayelet
	 	2 Beitar St, Jerusalem, Israel
	 	Fax 972-2-565-4001
	 	Attn: Harry Grynberg, Adv.

 

13.7       Severability.
If any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable under applicable law,
then such provision shall be excluded from this Agreement and the remainder of this Agreement shall be interpreted as if such provision
were so excluded and shall be enforceable in accordance with its terms; provided, however, that in such event this Agreement shall
be interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law, to the meaning and
intention of the excluded provision as determined by such court of competent jurisdiction.

 

13.8       Counterparts.
This Agreement may be executed in any number of counterparts (including counterparts transmitted by fax or by electronic
mail in PDF format), each of which shall be deemed an original and enforceable against the parties actually executing such counterpart,
and all of which together shall constitute one and the same instrument.

 

[Remainder of Page Intentionally Left Blank]

 

[Signature Pages Follow]

 

    	- 22 -

    	 

    

 

[Signature Page – Subscription Agreement]

 

IN WITNESS WHEREOF, the parties have
signed this Agreement as of the date first hereinabove set forth.

 

	Intec Pharma ltd.	 	Gabriel Capital Management (GP) Ltd. for and on behalf of a limited partnership in formation in the State of Delaware, USA, to be known as “Gabriel Capital Fund (US), L.P.” or such other name designated by Gabriel Capital Management (GP) Ltd.
	 	 
	By:	 GIORA CARNI	 
	 	 
	Signature:	 
	 	 
	 	/s/ Giora Carni	 	 
	 	INTEC PHARMA LTD.	 	 

	 	 	By:	 
	 	 	 	 
	 	 	Signature:

	Gabriel Capital Management (GP) Ltd. for and on behalf of a limited partnership
in formation in the State of Israel, to be known as “Gabriel Capital Fund (Israel), L.P.” or such
other name designated by Gabriel Capital Management (GP) Ltd.	 	 	 
	 	 
	 	 
	 	By:	 
	 	 	 
	 	Signature:
	 	 	 	 

 

	 	 	 
	By: 	 	 	 
	 	 	 
	Signature:	 	 
	 	 	 	 
	 	 	 
	 	 	 
	 	 	 	 
	By: 	 	 	By:	 
	 	 	 
	Signature:	 	Signature:
	 	 	 	 	 
	 	 	 
	Gabriel Capital Management Ltd.	 	 
	 	 	 
	By: 	 	 	 
	 	 	 
	Signature:	 	 
	 	 	 	 

 

 

    	- 23 -

    	 

    

 

[Signature Page – Subscription Agreement –
Intec Pharma Ltd]

 

IN WITNESS WHEREOF, the parties have
signed this Agreement as of the date first hereinabove set forth.

 

	Gabriel Capital Management (GP) Ltd. for and on behalf of a limited partnership in formation in the State of Delaware, USA, to be known as “Gabriel Capital Fund (US), L.P.” or such other name designated by Gabriel Capital Management (GP) Ltd.	 	Gabriel Capital Management (GP) Ltd. for and on behalf of a limited partnership in formation in the State of Israel, to be known as “Gabriel Capital Fund (Israel), L.P.” or such other name designated by Gabriel Capital Management (GP) Ltd.
	 	 	 
	By: 		 	By: 	
	Director	 	Director
		 	 
	Signature: 	 	Signature:
	 	 	 
	/s/ Gabriel Capital Management (GP) Ltd.	 	/s/ Gabriel Capital Management (GP) Ltd.
	 		 	 	
	 	 	 
	 	 	 
	 	 	 
	Gabriel Capital Management Ltd.	 	 
	 	 	 
	By:		 	 
	Director	 	 
	 	 	 
	Signature:	 	 
	 	 	 
	/s/ Gabriel Capital Management (GP) Ltd.	 	 
	 	 	 	 	 	 

SCHEDULES AND EXHIBITS TO FOLLOW

 

    	 

    	 

    

 

[Signature Page – Subscription
Agreement – Intec Pharma Ltd. – August [__], 2013]

 

IN WITNESS WHEREOF, the parties
have signed this Agreement as of the date first hereinabove set forth.

 

	Collace Service Ltd.	 	 
	 	 	 
	By:	Darren Toudic & Christopher Lees	 	 
	Director	 	 
	 	 	 
	Signature:	 	 
	 	/s/ Darren Toudic & Christopher Lees	 	 

 

[$250,000.00]

Amount of Subscription

 

SCHEDULES AND EXHIBITS TO FOLLOW

 

    	 

    	 

    

 

[Signature Page – Subscription
Agreement – Intec Pharma Ltd]

 

IN WITNESS WHEREOF, the parties
have signed this Agreement as of the date first hereinabove set forth.

 

	Sterling Group International Inc.	 	 
	 	 	 
	By:		 	 
	Director	 	 
	 	 	 
	Signature:	 	 
	 	 	 
	 	/s/ Sterling Group International Inc. 	 	 

  

SCHEDULES AND EXHIBITS TO FOLLOW

 

    	 

    	 

    

 

SCHEDULE A - The Subscribers

 

	 	 	 	 	 	Number of	 	 	Notice
	 	 	Subscription	 	 	Subscription	 	 	Details
	Name of Subscriber	 	Price	 	 	Shares	 	 	(address)
	Gabriel Capital Management
    (GP) Ltd. for and on behalf of a limited partnership in formation in
    the State of Delaware, USA, to be known as “Gabriel Capital Fund (US), L.P.” or
    such other name designated by Gabriel Capital Management (GP) Ltd.*	 	USD 	1,765,000	 	 	 	5,659,709	 	 	Technology Park, Building 1B, Malcha, Jerusalem 9651

 Fax +972 2 649 0401
	 	 	 	 	 	 	 	 	 	 	 
	Gabriel Capital Management (GP) Ltd.
    for and on behalf of a limited partnership in formation in the State
    of Israel, to be known as “Gabriel Capital Fund (Israel), L.P.” or
    such other name designated by Gabriel Capital Management (GP) Ltd.*	 	USD 	235,000	 	 	 	753,559	 	 	Technology Park, Building 1B, Malcha, Jerusalem 9651

 Fax +972 2 649 0401
	 	 	 	 	 	 	 	 	 	 	 
	Sterling Group International Inc.	 	USD 	250,000	 	 	 	801,659	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	Collace Services Ltd.	 	USD 	250,000	 	 	 	801,659	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	Gabriel Capital Management Ltd and/or
    such	 	$	0	 	 	$	0	 	 	 
	persons and/or entities (who are not purchasing any Subscription Shares) as to whom Gabriel Capital Management Ltd shall notify the Company in writing by prior to the Closing, which other persons and/or entities shall be deemed to be "Subscribers" for the purposes of this Agreement and whom, without being required to sign this Agreement, shall be deemed to be third-party beneficiaries to this Agreement for all relevant purposes hereof and who, for the avoidance of any doubt, shall be entitled (and/or for whom Gabriel Capital Management Ltd shall be entitled) to enforce the rights of a "Subscriber" under this Agreement insofar as they relate to the Warrants and Warrant Shares.	 	 	 	 	 	 	[i.e. Will receive zero Subscription Shares, but will be granted Warrants]	 	 	 

 

* Gabriel Capital may inform the Company of a different
allocation between the two funds up to two days prior to Closing. Without derogating from any of Gabriel Capital’s and such
funds’ rights, it is hereby clarified that either of the funds may also transfer shares and Warrants to the other fund following
the Closing, subject to the applicable lock up restrictions.

 

    	- 24 -

    	 

    

 

SCHEDULE B

 

Lock Up Restrictions

 

Section 15C of the Securities Law, 5728-1968 provides as follows:

 

“15C. Restrictions on resale of securities

 

(a) Notwithstanding the provisions of section 15B(3), the
following shall be regarded as offerings to the public:

 

(1) An offering in the course of trading
on a stock exchange of securities which are listed for trading thereon, and which were allotted to the offeror by an issuer in
an offer under section 15A(a)(1), (4) or (7), or in an offering made abroad not by way of a prospectus - if the period prescribed
in the regulations from the date of the allotment has not elapsed, or if additional periods as prescribed in regulations have not
yet elapsed and one of the following has occurred during each of the additional periods:

 

		(a)	The quantity of the offered securities exceeds the quantity
prescribed in the regulations;

 

		(b)	The percentage of the issued and paid-up capital which
is being offered by the corporation whose securities are being offered exceeds the percentage prescribed in the regulations;

 

The provisions of this paragraph shall
also apply to securities purchased during the said period or additional periods, other than in accordance with a prospectus and
not during the course of trading on a stock exchange, from the offeror or from a corporation under the control of the corporation
whose shares are being offered. These provisions shall also apply to securities resulting from the realization or conversion of
securities that were allotted as stated in this section. . .”

 

The periods referred to in section 15C above are as follows:

 

		(i)	Full lock up period – 6 months from the date
of issuance.

 

		(ii)	Additional periods – 6 consecutive quarters.

 

		(iii)	Permitted sales on the stock exchange in the Additional
periods – the amount sold in each Additional period is less than 1% of the issued and paid-up capital of the
company or; the amount of securities offered in each day in such period is lower than the daily average trading turnover on the
stock exchange of the security of the type offered in the period of 8 weeks preceding the date or offer.

 

    	- 25 -

    	 

    

 

SCHEDULE C

 

Joinder to Subscription Agreement Dated [______] [_]
2013

 

The undersigned hereby
consents to and agrees to be bound by all the terms, covenants and provisions of the Subscription Agreement dated [______]
[_], 2013 (the “Agreement”; all terms not otherwise defined herein shall have the meanings ascribed to such
terms in the Agreement) by and among Intec Pharma Ltd. and the Subscribers listed in Schedule A thereto.

 

All of the Subscription
Shares, Warrants, Warrant Shares, Additional Warrants and Additional Warrant Shares purchased by the undersigned are and shall
be subject to all of the rights, obligations, and restrictions described in the Agreement.

 

The undersigned acknowledges
and agrees that upon execution and delivery of this Joinder to the Agreement, it shall be deemed a Subscriber for all intents and
purposes of the Agreement.

 

Subscription Price                                          

 

The execution of this
Joinder shall constitute, for all intents and purposes, its execution of the Agreement, including without limitation for the purpose
of the representations and warrants of the Subscribers thereto.

 

	Date: 	 	 

 

	Signature: 	 	 

 

	By:	 	 

	Name: 	 	 

	Title :	 	 

 

	Address:	 	 

	 	 
	 	 
	 	 

 

The above is agreed to and confirmed by the undersigned:

 

_________________________

Intec Pharma Ltd.

By:

Title:

 

    	- 26 -

    	 

    

 

SCHEDULE C

 

Joinder to
Subscription Agreement Dated August 6, 2013

 

The undersigned
hereby consents to and agrees to be bound by all the terms, covenants and provisions of the Subscription Agreement dated August
6, 2013 (the “Agreement”; all terms not otherwise
defined herein shall have the meanings ascribed to such terms in the Agreement) by and among Intec Pharma Ltd. and the Subscribers
listed in Schedule A thereto.

 

All of the Subscription
Shares, Warrants, Warrant Shares, Additional Warrants and Additional Warrant Shares purchased by the undersigned are and shall
be subject to all of the rights, obligations, and restrictions described in the Agreement.

 

The undersigned acknowledges
and agrees that upon execution and delivery of this Joinder to the Agreement, it shall be deemed a Subscriber for all intents and
purposes of the Agreement.

 

Subscription
Price            US$
100,000

 

The execution of
this Joinder shall constitute, for all intents and purposes, its execution of the Agreement, including without limitation for the
purpose of the representations and  warrants of the Subscribers thereto.

 

	Date:	8/7/13	 

 

	 	 	 
	Signature	/s/ Joe Franco	 
	 	 	 
	Name: 	Joe Franco	 

  

	Address:	 
	17 Gateway DR	 
	Great Neck NY 11021	 
	 	 

 

The above is agreed to and confirmed by the undersigned:

 

INTEC PHARMA LTD.

 

	/s/ Zvi Joseph	 
	Intec Pharma Ltd.	 
	By: Zvi Joseph	 
	Title: Chairman	 

 

    	- 27 -

    	 

    

 

SCHEDULE C

 

Joinder to Subscription Agreement Dated August 6,
2013

 

The undersigned
hereby consents to and agrees to be bound by all the terms, covenants and provisions of the Subscription Agreement dated August
6, 2013 (the “Agreement”; all terms not otherwise defined herein shall have the meanings ascribed to such terms
in the Agreement) by and among Intec Pharma Ltd. and the Subscribers listed in Schedule A thereto.

 

All of the Subscription
Shares, Warrants, Warrant Shares, Additional Warrants and Additional Warrant Shares purchased by the undersigned are and shall
be subject to all of the rights, obligations, and restrictions described in the Agreement.

 

The undersigned
acknowledges and agrees that upon execution and delivery of this Joinder to the Agreement, it shall be deemed a Subscriber for
all intents and purposes of the Agreement.

 

Subscription
Price                         US$
2,000,000

 

The execution
of this Joinder shall constitute, for all intents and purposes, its execution of the Agreement, including without limitation for
the purpose of the representations and warrants of the Subscribers thereto.

 

	Date:	18/8/2013	 

 

	Signature:	/s/ Sphera Global
Healthcare Master Fund 	 

 

	Name of Subscriber:	Sphera Global
Healthcare Master Fund 	
	 	HFR HE Sphera Global Healthcare Master Trust	 

  

	Address:	 
	c/o Sphera Funds Mgmt.	 
	21 Ha’arba’ah
    St  4th Floor	 
	Tel-Aviv, Israel	 

 

	The above is agreed to and confirmed by the undersigned:
	 
	INTEC PHARMA LTD.
	 
	/s/ Giora Carni	 
	Intec Pharma Ltd	 
	By: Giora Carni	 
	Title: CEO	 

 

    	- 28 -

    	 

    

 

SCHEDULE C

 

Joinder to Subscription Agreement Dated August 6,
2013

 

The undersigned
hereby consents to and agrees to be bound by all the terms, covenants and provisions of the Subscription Agreement dated August
6, 2013 (the “Agreement”; all terms not otherwise
defined herein shall have the meanings ascribed to such terms in the Agreement) by and among lntec Pharma Ltd. and the Subscribers
listed in Schedule A thereto.

 

All of the
Subscription Shares, Warrants, Warrant Shares, Additional Warrants and Additional Warrant Shares purchased by the undersigned are
and shall be subject to all of the rights, obligations, and restrictions described in the Agreement.

 

The undersigned
acknowledges and agrees that upon execution and delivery of this Joinder to the Agreement, it shall be deemed a Subscriber for
all intents and purposes of the Agreement.

 

Subscription
Price               US$ 100,000

 

The execution
of this Joinder shall constitute, for all intents and purposes, its execution of the Agreement, including without limitation for
the purpose of the representations and warrants of the Subscribers thereto.

 

	Date:	August 6th, 2013	 

 

	Signature:	/s/ Steve
    Israel	 

 

	Name: Steve Israel  

  

	Address:	 
		 
		 
	 

 

	The above is agreed to and confirmed by the
    undersigned:	 
	 	 
	INTEC PHARMA LTD.	 
	 	 
	/s/ Zvi Joseph	 
	Intec Pharma Ltd.	 
	By: Zvi Joseph	 
	Title: Chairman	 

 

    	- 29 -

    	 

    

 

SCHEDULE C

 

Joinder to Subscription Agreement Dated August 6,
2013

 

The undersigned
hereby consents to and agrees to be bound by all the terms, covenants and provisions of the Subscription Agreement dated August
6, 2013 (the "Agreement"; all terms not otherwise defined
herein shall have the meanings ascribed to such terms in the Agreement) by and among Intec Pharma Ltd. and the Subscribers listed
in Schedule A thereto.

 

All of the
Subscription Shares, Warrants, Warrant Shares, Additional Warrants and Additional Warrant Shares purchased by the undersigned are
and shall be subject to all of the rights, obligations, and restrictions described in the Agreement,

 

The undersigned
acknowledges and agrees that upon execution and delivery of this Joinder to the Agreement, it shall be deemed a Subscriber for
all intents and purposes of the Agreement.

 

Subscription
Price         US$300,000

 

The execution
of this Joinder shall constitute, for all intents and purposes, its execution of the Agreement, including without limitation for
the purpose of the representations and warrants of the Subscribers thereto.

 

	Date:	  .8.13	 

 

	Signature:	/s/ Yehuda Shimoni	 

 

	Name of Subscriber:	Yehuda Shimoni	

  

	Address:	 
	57 Rothchild Blvd.	 
	Tel-Aviv 65785	 
	Isreal	 

	 
	The above is agreed to and confirmed by the undersigned:
	 
	INTEC PHARMA LTD.
	 
	/s/ Zvi Joseph	 
	Intec Pharma Ltd.	 
	By: Zvi Joseph	 
	Title: Chairman

 

    	- 30 -

    	 

    

   

SCHEDULE D

 

Exercise Notice

 Re: Warrant

 

To:        Intec Pharma Ltd

 

[_______________a Subscriber]
hereby elects to convert the Warrant in full/in part and purchase ___________ [number of] Ordinary Shares, NIS 0.01 each
par value each of Intec Pharma Ltd. as determined pursuant to the terms of the Subscription Agreement dated the _______
day of _________ 2013 between Intec Pharma Ltd. and the Subscribers, and tenders herewith payment of the Exercise Price
in full.

 

Please credit the following account with the Warrant Shares:

Account Name: [________]

Account Number: [____]

Bank: [____]

Branch : [____]

 

Capitalized terms that
are not defined in this Exercise Notice shall have the meanings ascribed to them in the said Subscription Agreement.

 

	 	 
	 	(Name)
	 	 
	 	 
	 	(Address)

 

    	- 31 -

    	 

    

 

SCHEDULE E

 

Second Exercise Notice

 

Re: Additional Warrant

 

To:        Intec Pharma Ltd.

 

[_______________a Subscriber]
hereby elects to convert the Additional Warrant in full/in part and purchase ___________ [number of] Ordinary Shares, NIS
0.01 each par value each of Intec Pharma Ltd. as determined pursuant to the terms of the Subscription Agreement dated the
_______ day of _________ 2013 between Intec Pharma Ltd. and the Subscribers, and tenders herewith payment of the Second
Exercise Price in full.

 

Please credit the following account
with the Additional Warrant Shares:

Account Name: [________]

Account Number: [____]

Bank: [____]

Branch : [____]

 

Capitalized terms that are not defined in
this Second Exercise Notice shall have the meanings ascribed to them in the said Subscription Agreement.

 

	 	 
	 	(Name)
	 	 
	 	 
	 	(Address)

 

    	- 32 -

    	 

    

 

Exhibit 3.1

 

Certificates of Warrants

 

    	 

    	 

    

 

Certificate of Warrant

 

Pursuant to the Subscription Agreement executed by and
between Intec Pharma Ltd. and _______, on August [__], 2013 (the "Agreement", "Company" and
"Subscriber", respectively), you are hereby granted __________ options exercisable into _______ of the Company's
ordinary shares par value NIS 0.01 each ("Ordinary Shares"), against the payment of the Exercise Price (as defined
below).

 

		1.	Definitions

 

"Warrant Shares" -
Ordinary Shares, which shall be equal in rights to the issued and outstanding ordinary shares of the Company, par value
NIS 0.01 each. The Warrant Shares will be registered in the name of Mizrahi Tfahot Registration Company Ltd;

 

"Exercise Price" -
NIS 1.2828 per share, as adjusted pursuant to the terms of this Certificate of Warrant and the Agreement;

 

"Date of Exercise"
- The date on which the Company received a written notice from the Subscriber subject to the exercise provisions as
detailed below;

 

"Date of Grant" -
_____________, 2013; 

 

"Options" - An
option to purchase Warrant Shares against the payment of the Exercise Price.

 

		2.	Vesting

 

All Options shall be fully vested
on the Date of Grant.

 

		3.	Exercise Period

 

The Options may be exercised over
a period of four (4) years as of _____________, 2013 ("Exercise Period") [4 YEARS FROM THE GABRIEL CLOSING DATE].
Any Options not exercised prior to the end of the Exercise Period will be cancelled and will not entitle their holder to any rights.

 

		4.	Exercise of Options

 

The Options can be exercised by
the Subscriber, in its sole discretion, in whole or in part, at any time during the Exercise Period (subject to the provisions
of Section 5.9 below). A written exercise notice will be submitted to the Company by the Subscriber. No later than three (3) days
after the delivery of such exercise notice the Subscriber will pay the Exercise Price for the Warrant Shares that are the subject
to the exercise notice by bank transfer in New Israeli Shekels and, following such payment, the Company will allot to the Subscriber
the amount of Ordinary Shares as per the exercise notice free and clear from any mortgages, charges, pledges, liens or encumbrances
whatsoever, will transfer to its registration company all the documents and information needed in order to deposit the Warrant
Shares of such Subscriber at its account which details shall be provided by such Subscriber to the Company in the exercise notice
and will submit all necessary reports to the Israeli Securities Authority and to the Tel Aviv Stock Exchange Ltd. ("TASE").
If the Options are exercised in part, the Company will issue replacement Certificate of Warrant for the balance of such Subscriber's
Options still outstanding),

 

		5.	Adjustments

 

As of the Date of Grant of the Options
and until the Options will be exercised or cancelled, the Company shall act as follows:

 

    	- 2 -

    	 

    

 

		5.1.	Adjustment for Share Splits and Reverse Splits.
In the event the Company at any time while any of the Options are outstanding shall subdivide or combine its Ordinary Shares,
the number of Ordinary Shares issuable upon exercise of a Subscriber's Options shall be proportionately increased or decreased,
as the case may be, and, for the avoidance of any doubt, the Exercise Price shall be proportionally adjusted.

 

For the avoidance of doubt, it is
hereby clarified that any share fractions that may result as of a share split or reverse split will be sold by the Company at TASE,
after accumulated to a reasonable amount to be sold at TASE, for a period of 30 days after the said adjustment. The net consideration,
after the deduction of any sale expenses, commissions and levies, shall be paid to the Subscribers within fourteen (14) days as
of the sale date as mentioned above. The Company will not issue checks in an amount less than NIS 30.

 

		5.2.	Adjustment for Dividends. If the Company, at any
time while the Options, or any portion thereof, remains outstanding and unexpired (the "Record Date"), shall
distribute to the holders of Ordinary Shares a dividend, whether payable out of earnings or surplus legally available for dividends
or by way of return of capital, then, immediately prior to the Record Date the Exercise Price shall be reduced by an amount equal
to the NIS amount of the per-share distribution on the Record Date fixed for the purpose of such distribution (the "Adjusted
Exercise Price"), but under no circumstances shall the Adjusted Exercise Price be lower than the face value of the Ordinary
Shares.

 

It is hereby clarified that in the
event: (i) the Subscriber(s) possesses a withholding tax exemption (the "Exemption"), the Exercise Price will
be equal to the Adjusted Exercise Price; (ii) the Subscriber(s) does not possess an Exemption, the Exercise Price shall be reduced
by an amount equal to the NIS amount of the per-share distribution on the Record Date fixed for the purpose of such distribution
net of applicable tax.

 

The Company will notify immediately
prior to the trade opening on the ex-dividend date, by way of an immediate report published on TASE site, of the Adjusted Exercise
Price. For the avoidance of doubt, no change in the base price Ordinary Share will occur.

 

		5.3.	Adjustment for Bonus Shares. In the event the Company
at any time while any of the Options are outstanding makes, or fixes a record date for the determination of holders of shares
entitled to receive bonus shares, the number of Warrant Shares exercisable upon exercise of the Options then outstanding shall
be adjusted such that it shall be increased by a number of Warrant Shares equal to the number of shares that such Subscriber would
have been entitled to receive in respect of the Warrant Shares for which the Options could have been exercised immediately prior
to the ex-bonus shares date. If any adjustments are made pursuant to this Section 5.3 the Subscribers will not be entitled to
any Ordinary Share fractions.

 

The Company will notify immediately
prior to the trade opening on the ex-bonus shares date, by way of an immediate report published on TASE site, of the adjustment
ratio.

 

		5.4.	Adjustment for Rights Offering. In the event the
Company at any time while any of the Options are outstanding makes, or fixes a record date for the determination of holders of
shares entitled to receive rights to purchase Ordinary Shares upon any rights offering by the Company, the Exercise Price will
not be adjusted, however, the number of Warrant Shares exercisable upon exercise of the Options then outstanding shall be adjusted
to the bonus component in the rights offering as being expressed by a fraction, the numerator of which shall be the closing price
of the Ordinary Shares as published by TASE on the last trading day immediately prior to the ex-rights date and the denominator
of which shall be the ex-rights base price per share as shall be published by TASE. If any adjustments are made pursuant to this
Section 5.4 the Subscribers will not be entitled to any Ordinary Share fractions.

 

    	- 3 -

    	 

    

 

The Company will notify immediately
prior to the trade opening on the ex-rights date, by way of an immediate report published on TASE site, of the adjustment ratio.

 

		5.5.	Adjustment for Pro-Rata Distributions. In the event
the Company, at any time while any of the Options are outstanding, distributes to holders of Ordinary Shares as a dividend any
asset other than cash or the Company's securities (in each case, “Distributed Property”), then forty-five (45)
days prior to the distribution of the Distributed Property, the Company shall issue a notice to the holders of the Options. Provided
that the holders of the Options did not exercise the Options within the said forty-five (45) days period, such holders will not
be entitled to receive the Distributed Property that such holders would have been entitled to receive in respect of the Warrant
Shares for which the Options could have been exercised immediately prior to the record date of such distribution.

 

		5.6.	Adjustment for Pro-Rata Distributions in Company Liquidation.
In the event a resolution for liquidation of the Company will be made, at any time while any of the Options are outstanding, the
Company shall publish an announcement in two daily widely distributed Hebrew newspapers, to state, inter alia, that each
holder of the Options will be considered as if he had exercised the Options prior to the said resolution (without prior paying
the Exercise Price) unless such holders of the Options will notify the Company thirty (30) days as of the said publication that
they waive his right to exercise the Options. Provided that a holder of the Options did not notify the Company of the said waiver
within the set time frame, then they will be entitled, pro-rata, to a dividend in cash that such holders would have been entitled
to receive in respect of the Warrant Shares for which the Options could have been exercised immediately prior to the record date
of such resolution for liquidation, deducting the Exercise Price of the said dividend, if any.

 

		5.7.	Adjustment for Merger Event. In the event there
shall be a Merger Event (as defined below) at any time while any of the Options are outstanding, then, subject to paragraph (viii)
below and as a part of such Merger Event, lawful provision shall be made so that Subscriber(s) shall thereafter be entitled to
receive, upon exercise of such Subscriber's Options, the number of Ordinary Shares or other securities or property of the successor
corporation resulting from such Merger Event that would have been issuable if such Subscriber had exercised such Subscriber's
Options immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Company's
Board of Directors with respect to all outstanding options and warrants issued by the Company) shall be made in the application
of the provisions of the Options with respect to the rights and interests of each Subscriber after the Merger Event to the end
that the provisions of the Subscribers' Options (including adjustments of the Exercise Price and/or number of Ordinary Shares
purchasable) shall be applicable in their entirety. Without limiting the foregoing and subject to paragraph (viii) below, in connection
with any Merger Event, upon the closing thereof, the successor or surviving entity shall assume the obligations of the Subscribers'
Options.

 

    	- 4 -

    	 

    

 

For the avoidance of any doubt, if
determined by the Company's Board of Directors in good faith that: (a) the implementation of the provisions of paragraph (vii)
above may impose an undue burden on the Company in the execution of a Merger Event, or (b) if the terms of such implementation
are not acceptable to the Subscribers or the Company - then the Subscribers shall have the right to execute a “cashless exercise”
in respect of such outstanding Options and the provisions of Section 3.6 to the Agreement shall apply, and the Company shall ensure
that adequate provision is made in the documents constituting the Merger Event and reasonable notice provided to the Subscribers
prior to the consummation of such Merger Event so that the Subscribers may implement the “cashless exercise” and participate
accordingly. Options not exercised under this provision or not otherwise exercised prior to the consummation of the Merger Event,
shall be void and null.

 

“Recapitalization Event”
means all that was provided in sub-sections 5.1-5.6 of this Section 5, as the case may be, or any other recapitalization, reclassification
or similar event resulting in a change of such Ordinary Shares into a different number of shares of the same class or any other
class or classes of shares.

 

“Merger
Event” means a merger or consolidation involving the Company in which the Company is not the surviving entity, or in
which the outstanding shares of the Company’s Ordinary Shares are otherwise converted into or exchanged for shares of capital
of another entity.

 

		5.8.	The contemplated adjustments under this Section 5 will
not be subject to any amendments.

 

		5.9.	Subject to TASE Rules and Regulations with respect to the
transition of the clearing to T+1 regarding shares and convertible securities, no Options will be exercised on the record date
concerning (a) bonus shares distribution, (b) rights issuance, (c) dividend distribution, (d) stock split, (e) stock consolidation,
or (f) capital reduction (each of the above “Corporate Event”). In case that the “Ex-Date” for
a Corporate Event shall occur before the record date for such Corporate Event, the Options may not be exercised on the said “Ex-Date”.

 

		6.	Cashless Exercise

 

Notwithstanding the foregoing, in
lieu of exercising a proportion of each of the Subscriber's Warrants as provided above, in whole or in part, such Subscriber may
elect to receive Ordinary Shares equal to the value of its Warrants so exercised (or the portion thereof being canceled), by written
notice of such election to the Company, at the principal office of the Company, in which event, the Company shall issue to such
Subscriber, for no additional consideration except for the payment of the par value thereof or, the minimum required by TASE at
the time of exercise (currently NIS 0.10 per share), that number of Ordinary Shares computed using the following formula:

 

	 	 	Y (A - B)
	X	=	—————
	 	 	A

 

		X	equals the number of Ordinary Shares to be issued to such Subscriber;

 

		Y	equals the number of Ordinary Shares which would otherwise have been purchasable under the portion
of such Subscriber's Warrant being exercised, at the time of exercise pursuant to this formula (or the portion thereof being canceled);

 

    	- 5 -

    	 

    

 

		A	shall equal the “Fair Value” of one share of the Company's Ordinary Shares. Fair Value
shall mean in the event that such Subscriber's  Warrant is exercised in accordance with the above formula: the price
per share equal to the average of the closing sale prices for the Ordinary Shares of the Company as reported on the Tel-Aviv Stock
Exchange or, should the Company’s shares be traded only on a different stock exchange, such stock exchange, for a consecutive
period of ten (10) trading days immediately prior to the date of exercise (i.e. delivery of Exercise Notice); and

 

		B	equals such Subscriber's Exercise Price in effect at the time of exercise pursuant to this formula.

 

		7.	Protection

 

Without derogating from the terms
of the Agreement and this Certificate of Warrant, the protections as specified in the Company's immediate report (ref. number:
2013-01-039597) with respect to the grant of options to Meitav Group and the Phoenix Group and as specified in the Company's prospectus
with respect to published on February 10, 2010, shall apply, mutatis mutandis, to the grant of Options contemplated herein.

 

		8.	No Assignment

 

The Options are non transferable,
non assignable, cannot be mortgaged, etc., except to an entity controlled by, controlling, or under common control with, the Subscriber
or to the partners, members or shareholders of the Subscriber.

 

		9.	Restrictions

 

The Subscriber acknowledges that
it is familiar with the provisions of the Securities Law 1968 and the Securities Law Regulations (Details with regard to Sections
15A to 15C of the Law), 2000, and is committed to act in accordance with such provisions, regarding restrictions on reselling the
Warrant Shares.

 

		10.	Taxation

 

The Subscriber acknowledges that
any tax liability with regards to the Options will be imposed solely on the Subscriber.

 

		11.	Options Registry

 

The Company shall keep a registry
of the option holders and will record their names, addresses and the issued option amounts (the "Registry"). Any
option holder is entitled to review the Registry at any reasonable time.

 

	 	Sincerely,
	 	 
	 	Intec Pharma Ltd.

 

    	- 6 -

    	 

    

 

Exhibit 4.1

 

Certificates of Additional Warrants

 

    	 

    	 

    

 

Certificate of Warrant

 

Pursuant to the Subscription Agreement executed by
and between Intec Pharma Ltd. and _______, on August____, 2013 (the "Agreement", "Company"
and "Subscriber", respectively), you are hereby granted __________ options exercisable into _______ of the
Company's ordinary shares par value NIS 0.01 each ("Ordinary Shares"), against the payment of the Exercise
Price (as defined below).

 

		1.	Definitions

 

"Warrant Shares" -
Ordinary Shares, which shall be equal in rights to the issued and outstanding ordinary shares of the Company, par value
NIS 0.01 each. The Warrant Shares will be registered in the name of Mizrahi Tfahot Registration Company Ltd;

 

"Exercise Price" -
NIS 1.2828 per share, as adjusted pursuant to the terms of this Certificate of Warrant and the Agreement;

 

"Date of Exercise"
- The date on which the Company received a written notice from the Subscriber subject to the exercise provisions as
detailed below;

 

"Date of Grant" -
October 1, 2014; 

 

"Options" - An
option to purchase Warrant Shares against the payment of the Exercise Price.

 

		2.	Vesting

 

All Options shall be fully vested
on the Date of Grant.

 

		3.	Exercise Period

 

The Options may be exercised at
any time after October 1, 2014 and prior to September 30, 2016. Any Options not exercised prior to the end of the Exercise Period
will be cancelled and will not entitle their holder to any rights.

 

		4.	Exercise of Options

 

The Options can be exercised by
the Subscriber, in its sole discretion, in whole or in part, at any time during the Exercise Period (subject to the provisions
of Section 5.9 below). A written exercise notice will be submitted to the Company by the Subscriber. No later than three (3) days
after the delivery of such exercise notice the Subscriber will pay the Exercise Price for the Warrant Shares that are the subject
to the exercise notice by bank transfer in New Israeli Shekels and, following such payment, the Company will allot to the Subscriber
the amount of Ordinary Shares as per the exercise notice free and clear from any mortgages, charges, pledges, liens or encumbrances
whatsoever, will transfer to its registration company all the documents and information needed in order to deposit the Warrant
Shares of such Subscriber at its account which details shall be provided by such Subscriber to the Company in the exercise notice
and will submit all necessary reports to the Israeli Securities Authority and to the Tel Aviv Stock Exchange Ltd. ("TASE").
If the Options are exercised in part, the Company will issue replacement Certificate of Warrant for the balance of such Subscriber's
Options still outstanding),

 

		5.	Adjustments

 

As of the Date of Grant of the Options
and until the Options will be exercised or cancelled, the Company shall act as follows:

 

    	- 2 -

    	 

    

 

		5.1.	Adjustment for Share Splits and Reverse Splits.
In the event the Company at any time while any of the Options are outstanding shall subdivide or combine its Ordinary Shares,
the number of Ordinary Shares issuable upon exercise of a Subscriber's Options shall be proportionately increased or decreased,
as the case may be, and, for the avoidance of any doubt, the Exercise Price shall be proportionally adjusted.

 

For the avoidance of doubt, it is
hereby clarified that any share fractions that may result as of a share split or reverse split will be sold by the Company at TASE,
after accumulated to a reasonable amount to be sold at TASE, for a period of 30 days after the said adjustment. The net consideration,
after the deduction of any sale expenses, commissions and levies, shall be paid to the Subscribers within fourteen (14) days as
of the sale date as mentioned above. The Company will not issue checks in an amount less than NIS 30.

 

		5.2.	Adjustment for Dividends. If the Company, at any
time while the Options, or any portion thereof, remains outstanding and unexpired (the "Record Date"), shall
distribute to the holders of Ordinary Shares a dividend, whether payable out of earnings or surplus legally available for dividends
or by way of return of capital, then, immediately prior to the Record Date the Exercise Price shall be reduced by an amount equal
to the NIS amount of the per-share distribution on the Record Date fixed for the purpose of such distribution (the "Adjusted
Exercise Price"), but under no circumstances shall the Adjusted Exercise Price be lower than the face value of the Ordinary
Shares.

 

It is hereby clarified that in the
event: (i) the Subscriber(s) possesses a withholding tax exemption (the "Exemption"), the Exercise Price will
be equal to the Adjusted Exercise Price; (ii) the Subscriber(s) does not possess an Exemption, the Exercise Price shall be reduced
by an amount equal to the NIS amount of the per-share distribution on the Record Date fixed for the purpose of such distribution
net of applicable tax.

 

The Company will notify immediately
prior to the trade opening on the ex-dividend date, by way of an immediate report published on TASE site, of the Adjusted Exercise
Price. For the avoidance of doubt, no change in the base price Ordinary Share will occur.

 

		5.3.	Adjustment for Bonus Shares. In the event the Company
at any time while any of the Options are outstanding makes, or fixes a record date for the determination of holders of shares
entitled to receive bonus shares, the number of Warrant Shares exercisable upon exercise of the Options then outstanding shall
be adjusted such that it shall be increased by a number of Warrant Shares equal to the number of shares that such Subscriber would
have been entitled to receive in respect of the Warrant Shares for which the Options could have been exercised immediately prior
to the ex-bonus shares date. If any adjustments are made pursuant to this Section 5.3 the Subscribers will not be entitled to
any Ordinary Share fractions.

 

The Company will notify immediately
prior to the trade opening on the ex-bonus shares date, by way of an immediate report published on TASE site, of the adjustment
ratio.

 

		5.4.	Adjustment for Rights Offering. In the event the
Company at any time while any of the Options are outstanding makes, or fixes a record date for the determination of holders of
shares entitled to receive rights to purchase Ordinary Shares upon any rights offering by the Company, the Exercise Price will
not be adjusted, however, the number of Warrant Shares exercisable upon exercise of the Options then outstanding shall be adjusted
to the bonus component in the rights offering as being expressed by a fraction, the numerator of which shall be the closing price
of the Ordinary Shares as published by TASE on the last trading day immediately prior to the ex-rights date and the denominator
of which shall be the ex-rights base price per share as shall be published by TASE. If any adjustments are made pursuant to this
Section 5.4 the Subscribers will not be entitled to any Ordinary Share fractions.

 

    	- 3 -

    	 

    

 

The Company will notify immediately
prior to the trade opening on the ex-rights date, by way of an immediate report published on TASE site, of the adjustment ratio.

 

		5.5.	Adjustment for Pro-Rata Distributions. In the event
the Company, at any time while any of the Options are outstanding, distributes to holders of Ordinary Shares as a dividend any
asset other than cash or the Company's securities (in each case, “Distributed Property”), then forty-five (45)
days prior to the distribution of the Distributed Property, the Company shall issue a notice to the holders of the Options. Provided
that the holders of the Options did not exercise the Options within the said forty-five (45) days period, such holders will not
be entitled to receive the Distributed Property that such holders would have been entitled to receive in respect of the Warrant
Shares for which the Options could have been exercised immediately prior to the record date of such distribution.

 

		5.6.	Adjustment for Pro-Rata Distributions in Company Liquidation.
In the event a resolution for liquidation of the Company will be made, at any time while any of the Options are outstanding, the
Company shall publish an announcement in two daily widely distributed Hebrew newspapers, to state, inter alia, that each
holder of the Options will be considered as if he had exercised the Options prior to the said resolution (without prior paying
the Exercise Price) unless such holders of the Options will notify the Company thirty (30) days as of the said publication that
they waive his right to exercise the Options. Provided that a holder of the Options did not notify the Company of the said waiver
within the set time frame, then they will be entitled, pro-rata, to a dividend in cash that such holders would have been entitled
to receive in respect of the Warrant Shares for which the Options could have been exercised immediately prior to the record date
of such resolution for liquidation, deducting the Exercise Price of the said dividend, if any.

 

		5.7.	Adjustment for Merger Event. In the event there
shall be a Merger Event (as defined below) at any time while any of the Options are outstanding, then, subject to paragraph (viii)
below and as a part of such Merger Event, lawful provision shall be made so that Subscriber(s) shall thereafter be entitled to
receive, upon exercise of such Subscriber's Options, the number of Ordinary Shares or other securities or property of the successor
corporation resulting from such Merger Event that would have been issuable if such Subscriber had exercised such Subscriber's
Options immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Company's
Board of Directors with respect to all outstanding options and warrants issued by the Company) shall be made in the application
of the provisions of the Options with respect to the rights and interests of each Subscriber after the Merger Event to the end
that the provisions of the Subscribers' Options (including adjustments of the Exercise Price and/or number of Ordinary Shares
purchasable) shall be applicable in their entirety. Without limiting the foregoing and subject to paragraph (viii) below,
in connection with any Merger Event, upon the closing thereof, the successor or surviving entity shall assume the obligations of
the Subscribers' Options.

 

    	- 4 -

    	 

    

 

For the avoidance of any doubt,
if determined by the Company's Board of Directors in good faith that: (a) the implementation of the provisions of paragraph (vii)
above may impose an undue burden on the Company in the execution of a Merger Event, or (b) if the terms of such implementation
are not acceptable to the Subscribers or the Company - then the Subscribers shall have the right to execute a “cashless exercise”
in respect of such outstanding Options and the provisions of Section 3.6 to the Agreement shall apply, and the Company shall ensure
that adequate provision is made in the documents constituting the Merger Event and reasonable notice provided to the Subscribers
prior to the consummation of such Merger Event so that the Subscribers may implement the “cashless exercise” and participate
accordingly. Options not exercised under this provision or not otherwise exercised prior to the consummation of the Merger Event,
shall be void and null.

 

“Recapitalization Event”
means all that was provided in sub-sections 5.1-5.6 of this Section 5, as the case may be, or any other recapitalization, reclassification
or similar event resulting in a change of such Ordinary Shares into a different number of shares of the same class or any other
class or classes of shares.

 

“Merger
Event” means a merger or consolidation involving the Company in which the Company is not the surviving entity, or in
which the outstanding shares of the Company’s Ordinary Shares are otherwise converted into or exchanged for shares of capital
of another entity.

 

		5.8.	The contemplated adjustments under this Section 5 will
not be subject to any amendments.

 

		5.9.	Subject to TASE Rules and Regulations with respect to the
transition of the clearing to T+1 regarding shares and convertible securities, no Options will be exercised on the record date
concerning (a) bonus shares distribution, (b) rights issuance, (c) dividend distribution, (d) stock split, (e) stock consolidation,
or (f) capital reduction (each of the above “Corporate Event”). In case that the “Ex-Date” for
a Corporate Event shall occur before the record date for such Corporate Event, the Options may not be exercised on the said “Ex-Date”.

 

		6.	Cashless Exercise

 

Notwithstanding the foregoing, in
lieu of exercising a proportion of each of the Subscriber's Warrants as provided above, in whole or in part, such Subscriber may
elect to receive Ordinary Shares equal to the value of its Warrants so exercised (or the portion thereof being canceled), by written
notice of such election to the Company, at the principal office of the Company, in which event, the Company shall issue to such
Subscriber, for no additional consideration except for the payment of the par value thereof or, the minimum required by TASE at
the time of exercise (currently NIS 0.10 per share), that number of Ordinary Shares computed using the following formula:

 

	 	 	Y (A - B)
	X	=	—————
	 	 	A

 

		X	equals the number of Ordinary Shares to be issued to such Subscriber;

 

		Y	equals the number of Ordinary Shares which would otherwise have been purchasable under the portion
of such Subscriber's Warrant being exercised, at the time of exercise pursuant to this formula (or the portion thereof being canceled);

 

    	- 5 -

    	 

    

 

		A	shall equal the “Fair Value” of one share of the Company's Ordinary Shares. Fair Value
shall mean in the event that such Subscriber's Warrant is exercised in accordance with the above formula: the price per share equal
to the average of the closing sale prices for the Ordinary Shares of the Company as reported on the Tel-Aviv Stock Exchange or,
should the Company’s shares be traded only on a different stock exchange, such stock exchange, for a consecutive period of
ten (10) trading days immediately prior to the date of exercise (i.e. delivery of Exercise Notice); and

 

		B	equals such Subscriber's Exercise Price in effect at the time of exercise pursuant to this formula.

 

		7.	Protection

 

Without derogating from the terms
of the Agreement and this Certificate of Warrant, the protections as specified in the Company's immediate report (ref. number:
2013-01-039597) with respect to the grant of options to Meitav Group and the Phoenix Group and as specified in the Company's prospectus
with respect to published on February 10, 2010, shall apply, mutatis mutandis, to the grant of Options contemplated herein.

 

		8.	No Assignment

 

The Options are non transferable,
non assignable, cannot be mortgaged, etc., except to an entity controlled by, controlling, or under common control with, the Subscriber
or to the partners, members or shareholders of the Subscriber.

 

		9.	Restrictions

 

The Subscriber acknowledges that
it is familiar with the provisions of the Securities Law 1968 and the Securities Law Regulations (Details with regard to Sections
15A to 15C of the Law), 2000, and is committed to act in accordance with such provisions, regarding restrictions on reselling the
Warrant Shares.

 

		10.	Taxation

 

The Subscriber acknowledges that
any tax liability with regards to the Options will be imposed solely on the Subscriber.

 

		11.	Options Registry

 

The Company shall keep a registry
of the option holders and will record their names, addresses and the issued option amounts (the "Registry"). Any
option holder is entitled to review the Registry at any reasonable time.

 

	 	Sincerely,
	 	 
	 	Intec Pharma Ltd.

 

    	- 6 -

    	 

    

 

Exhibit 9(f)

 

Capitalization Table

 

	 	 	 	 	 	 	 	 	 	 	Issued and Outstanding	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	Issued and	 	 	share capital including	 	 	 	 	 	 	 
	 	 	 	 	Security	 	 	Outstanding share	 	 	the benefit rate derived	 	 	Exercise	 	 	Expiration	 
	Securities Holder	 	 Security Name	 	Number	 	 	capital	 	 	from rights issuances	 	 	Price	 	 	Date	 
	Registration Co. of United Mizrahi Bank Ltd.	 	Ordinary shares	 	 	1117795	 	 	 	211,465,322	 	 	 	211,465,322	 	 	 	—	 	 	 	—	 
	Registration Co. of United Mizrahi Bank Ltd.	 	Options (series 1)*	 	 	1117803	 	 	 	15,679,380	 	 	 	16,411,607	 	 	 	1.2 NIS	 	 	 	09.02.2014	 
	S.G.S. Trust Ltd.	 	Non-Tradable Warrant for employees, consultants and service providers**	 	 	1117837	 	 	 	23,774,823	 	 	 	23,774,823	 	 	 	—	 	 	 	—	 
	Meitav Mutual Fund Management (1982) Ltd.	 	Non-Tradable Warrants for Institutions 2010*	 	 	1121292	 	 	 	322,850	 	 	 	337,927	 	 	 	1.38 NIS	 	 	 	21.10.2014	 
	Meitav Gemel Ltd.	 	Non-Tradable Warrants for Institutions 2010*	 	 	1121292	 	 	 	1,562,500	 	 	 	1,635,469	 	 	 	1.38 NIS	 	 	 	21.10.2014	 
	The Phoenix Holdings Ltd.	 	Non-Tradable Warrants for Institutions 2010*	 	 	1121292	 	 	 	3,298,330	 	 	 	3,452,362	 	 	 	1.38 NIS	 	 	 	21.10.2014	 
	Meitav Gemel Ltd.	 	Non-Tradable Warrants for Institutions 2013**	 	 	1127968	 	 	 	800,000	 	 	 	800,000	 	 	 	1.60 NIS	 	 	 	13.02.2015	 
	The Phoenix Holdings Ltd.- Nostro	 	Non-Tradable Warrants for Institutions 2013**	 	 	1127968	 	 	 	461,600	 	 	 	461,600	 	 	 	1.60 NIS	 	 	 	13.02.2015	 
	The Phoenix Holdings Ltd.- Gemel and Pension	 	Non-Tradable Warrants for Institutions 2013**	 	 	1127968	 	 	 	609,000	 	 	 	609,000	 	 	 	1.60 NIS	 	 	 	13.02.2015	 
	The Phoenix Holdings Ltd.- Participant	 	Non-Tradable Warrants for Institutions 2013**	 	 	1127968	 	 	 	2,749,400	 	 	 	2,749,400	 	 	 	1.60 NIS	 	 	 	13.02.2015	 

 

(*)   Each of the options and warrants is convertible
into 1.0467 Ordinary Shares.

 

(**) Each of the options and warrants is convertible
into one (1) Ordinary Share.Exhibit 10.9

 

 

 

	March 29, 2013	 
	 
	Nadav Navon, PhD, MBA
	Intec Pharma
	12 Hartom St, P.O.B 45219, Jerusalem 91450
	Israel
	 
	Re: MJFF Research Grant 2013
	 
	Project Title: “Oral Toxicity Study in Goettingen Pigs with 30-Day Recovery (GLP”
	 
	Dear Dr. Navon:
	 
	On behalf of the Board of Directors of The Michael J. Fox Foundation for Parkinson’s Research (MJFF), it is a pleasure to make this award in the amount of $704,479.25 to conduct the research described in your proposal, “Oral Toxicity Study in Goettingen Pigs with 30-Day Recovery (GLP.”
	 
	This nine-month award is offered based on your representation that you have no overlapping grants or additional funding for this work. Please contact MJFF immediately if at any time during this period additional third-party funding is sought or received, or if circumstances arise prohibiting completion of your project on schedule. The terms and conditions governing this award are detailed in the attached agreement. Please read it carefully and contact us with any questions.
	 
	To accept this award,
    please sign the enclosed agreement (including appropriate institutional sign-off). Please scan the signed agreement and send
    electronically to AHARRIS@michaeljfox.org. We ask that you return a signed agreement no later than April 5, 2013. If
    you do not wish to accept finding, please notify MJFF as soon as possible.
	 
	The Michael J. Fox Foundation for Parkinson’s Research is enthusiastic about supporting your research and wishes you utmost success with this project and all your pursuits. Congratulations!
	 
	Sincerely,
	 
	/s/ Joanne Martz
	Joanne Martz
	Chief Financial and Administrative Officer
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

 

Grand Central Station • P.O. Box 4777 • New York, NY
10163-4777 • Tel. 212-509-0995 • Fax 212-509-2390 • www.michaeljfox.org

 

    	 

    	 

    

 

 

 

	The Michael J. Fox Foundation for Parkinson’s Research	
	Award Terms and Conditions — MJFF Research Grant 2013
	 
	Principal Investigator(s): Nadav Navon, PhD, MBA
	 
	The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is pleased to make you this award (the “Award”) to support the work described in your application, “Oral Toxicity Study in Goettingen Pigs with 30-Day Recovery (GLP.” (the “Project”). In accepting this Award, you and your institution (collectively, “You” or “you”) agree to the following terms and conditions in this Agreement.
	 
	1.      Sources of Funds 
	 
	This Award is made with the understanding that your Project currently has no additional sources of funding and does not overlap with any existing grants. You agree that you will neither solicit nor accept additional funding for this Project without prior written notice to MJFF. If there is overlap between this Award and another grant made to you by another third party, MJFF will renegotiate the budget of this Award with you (a copy of the final budget is provided with this Agreement as Appendix A) and reserves the right to provide less funding than identified in this Award or obtain a refund from you, so that funding from this Award does not overlap with another grant. If you receive additional funding for your Project without MJFF’s advance written consent, MJFF reserves the rights to withhold funding and require repayment of this Award if it is not satisfied, in its reasonable discretion, that the additional funding is for incremental research activity which does not overlap with this Award or conflict with your ability to perform the Project.
	 
	2.      Use of Funds 
	 
	2.1      Funds awarded by MJFF are to be used solely for the Project and are conditioned on your meeting certain milestones and deliverables, which are attached  at Appendix B, timely delivery of expense and progress reports and participation in MJFF sponsored meetings at which your progress will be assessed. MJFF assessments are based on review of your progress at regular intervals, determination of the quality of the scientific research performed, and its continued high relevance to Parkinson’s disease (“MJFF Assessment Criteria”). In exchange, MJFF agrees to pay all direct costs for this Project, in addition to indirect costs with a limit of up to 10% of direct costs. For this Award, funds are allotted in the amount of $640,435.68 direct costs, and $64,043.57, indirect costs. Any unused funds at the end of the Award period, as detailed in a final expense report, must be returned to MJFF within one month from the submission of the expense report. You shall maintain complete and accurate books, records and accounts that, in reasonable detail, fairly reflect the use of the Award. MJFF shall have the right to review and audit such books, records and accounts at a mutually convenient time upon prior written notice to you.
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

 

Grand Central Station • P.O. Box 4777 • New York, NY
10163-4777 • Tel. 212-509-0995 • Fax 212-509-2390 • www.michaeljfox.org

 

    	 

    	 

    

 

 

 

2.2        The
Award is to be used as budgeted and reflected in the milestones. Any alterations, amendments, or changes in the specific goals
or budget of the Project will require the review and pre-approval of MJFF. Examples of such alterations or amendments include (but
are not limited to): transfer of a Principal Investigator (“PI”) from one institution to another, adding or deleting
a specific Project goal, budget reallocation, or modification of proposed workload and milestones. Please note that MJFF funds
shall not be used for travel or equipment costs not approved in the budget as awarded (see Appendix A). 

 

2.3        If
you request a change to the Award, you must submit a written request for approval detailing the requested change and
associated rationale in advance to a member of the MJFF research team. Failure to obtain prior approval for any changes in
work timeline, milestones or budget may result in revocation of funding in whole or part. You agree that funds expended by
you either not in accordance with the approved Project or prior to pre-approval of any material change to are both (i)
recoverable by, and subject to restitution by you to, MJFF and (ii) may be cause for immediate termination of funding by
MJFF.

 

		3.	Grant Timeline 

 

3.1        MJFF expects
that your Project will be completed according to the agreed timeline attached at Appendix B. Continued funding also is contingent
on demonstrated progress and satisfactory assessment by MJFF. To this end, you are required to do the following:

 

		(a)	Provide written proof of Institutional Animal Care and Use Committee (“IACUC”) approval
one month from date of award notification (March 29, 2013). Payment to begin work will not be issued without IACUC approval.

 

		(b)	Confirm in writing that all personnel (including technicians and post-doctoral fellows) have been
hired by the third month of the project, or that any delay in hiring has not postponed progress on the work described. MJFF will
contact awardees at the three-month mark of the Award for such confirmation. Failure to meet this requirement may result in withholding
of further payment.

 

		(c)	Participate in regularly scheduled assessment meetings and/or teleconferences. Failure to participate
in these assessments and to demonstrate satisfactory progress may result in withholding of future payments.

 

		(i)	The first assessment will be held at the six-month mark of your Award by teleconference to review
initial progress.

 

		(ii)	An assessment meeting will be held at the completion of your Award; The individual awardee is required
to attend assessment meetings in person, unless otherwise informed by MJFF.

 

		(d)	Complete
                                         progress and expense reports detailing your progress against milestones and your associated
                                         expenditures. These reports will be due before the assessment meeting at the completion
                                         of your award. When appropriate, additional reports may be requested before other assessment
                                         meetings and teleconferences. Templates will be provided to you to facilitate this reporting.
                                         These reports will be reviewed by MJFF against the MJFF Assessment Criteria; MJFF may
                                         thereafter provide you with suggestions, critique, and feedback.

 

    	 

    	 

    

 

 

 

		(e)	Participate openly in discussions regarding your Project with MJFF’s scientific and research
staff, and advisors.

 

3.2        Failure to meet
milestones, furnish scheduled deliverables, including any reports, satisfactorily meet MJFF Assessment Criteria or comply with
this Agreement may serve as one or more bases for termination of funding by MJFF.

 

3.3        If
at any time circumstances arise that prohibit completion of the Project on schedule, you are required to notify MJFF
immediately. MJFF will consider granting ONE no-cost extension per project on a case by case basis. To apply for a no-cost
extension, submit a letter detailing the request. The letter should include reasons for delays or changes, associated
rationale, a timeline for continuing the work, and an expense report detailing remaining funds.

 

		4.	Payment Schedule 

 

4.1        Subject to the foregoing conditions,
MJFF intends to pay your Award on the installment schedule outlined in the Milestones Appendix B document.

 

4.2        MJFF reserves the right to change
this schedule if necessary and will notify you and/or your administrator in writing in that event.

 

		5.	Confidentiality 

 

5.1        MJFF treats
all pre-proposals, applications, research projects, associated research information and underlying data (collectively, the “Confidential
Information”) as confidential, using no less than reasonable care in protecting the Confidential Information from disclosure
to third parties who do not participate in the application review and assessment processes. All Confidential Information will be
used by MJFF for the purposes of reviews and assessments, and will be shared only in accordance with its Sharing Policy (see Section
7 below). Such obligations cover any information retained in the unaided memories of persons participating in reviews and assessments
and may not be used without the permission of the disclosing party. Notwithstanding the foregoing, the obligations governing the
disclosure and use of Confidential Information do not apply with respect to Confidential Information that:

 

		(a)	was generally known to the public at the time of disclosure;

 

		(b)	becomes generally known to the public through no unlawful or unauthorized act or omission, or violation
of this Agreement, by any recipient of Confidential Information, ;

 

		(c)	was independently developed by any recipient prior to disclosure; or

 

		(d)	was disclosed to a recipient by a third party who has the right
                                                                                                        to make such disclosure. 

 

    	 

    	 

    

 

 

 

5.2        Provided that subsections
(a)-(d) above do not become applicable, if any recipient of Confidential Information is asked to produce any Confidential Information
pursuant to a legal or governmental proceeding, such recipient shall give the applicant or other owner of such Confidential Information
(the “Discloser”) as much prior notice of such request as is reasonably practicable, under the circumstances and shall
use its reasonable efforts to assist the Discloser of such Confidential Information in defending Discloser’s rights (at Discloser’s
cost), including objecting to such request, obtaining confidential treatment for Confidential Information, disclosing only that
portion of the Confidential Information responsive to a judicial or governmental order, and providing Discloser with any copies
of Confidential Information so disclosed.

 

		6.	Data Underlying Research Information to be Included with Progress Reports

 

With each progress report,
you agree to provide MJFF, in a format prescribed by it, the data underlying your research information for each milestone (the
“Data”). MJFF and its grant assessors will use the Data to assess your progress toward achieving the milestones.

 

		7.	Sharing Policy 

 

7.1        As
MJFF is a public charity, research conducted with funds from MJFF (“Research”) must be conducted in the public interest
MJFF acknowledges that discoveries and related regulatory approvals made by researchers under its sponsorship are the property
of those conducting and responsible for the Research and that unless otherwise agreed to by the parties, such researchers shall
have the first opportunity to exploit the Research commercially or otherwise.

 

		7.2	Notwithstanding the foregoing, you agree that MJFF:

 

		(a)	may retain the Data and that MJFF may, 90 or more days after expiration of the Award, make
                                                                the Data available to MJFF employees, consultants, grant recipients and others affiliated with MJFF through a secure medium
                                                                to advance scientific discovery. This subsection shall not prohibit MJFF from making the Data available before expiration of
                                                                the grant to persons executing MJFF’s Confidential Disclosure Agreement for the purpose of assessing your progress
                                                                toward achieving the milestones. If the Data ceases to be Confidential Information as described in subsections (a)-(d) of
                                                                MJFF’s Confidentiality policy, then these restrictions on dissemination shall not apply;

 

		(b)	may, after reasonable consultation which will not be unreasonably denied, conditioned or delayed
by you, publicly release a summary of findings of the research 90 or more days after expiration of the Award; and,

 

		(c)	may make all tools or reagents (i)
                                                                                                                              funded by and (ii) that result from awarded projects (collectively, the “Results”) readily available to the
                                                                                                                              community including MJFF for research purposes 90 or more days after expiration of the Award. You agree that you will
                                                                                                                              cooperate and collaborate with MJFF and other researchers and share access to Results on fair and reasonable terms and
                                                                                                                              conditions. By signing this Agreement, you and your institution are confirming that you are not aware of any requirements
                                                                                                                              that would prohibit, delay,
                                                                                                                              or restrict your ability to share your Results from this initiative, including requirements of third-party collaborators
                                                                                                                              or companies with which you are affiliated.

 

    	 

    	 

    

 

 

 

		(d)	Notwithstanding the 90-day periods set forth in subsections (a)-(c) above, MJFF will consider
                                                                  a request by you to delay the availability of Data, a summary and/or the Results in order to complete any necessary
                                                                  intellectual property filings.

 

		8.	Liability 

 

You acknowledge that MJFF
is solely a passive grantor, and you hereby agree to indemnify, defend and hold MJFF, its directors, trustees, officers, employees,
agents and consultants harmless in connection with all liability directly or indirectly arising out of the Project, including all
associated costs, damages and expenses and reasonable attorney’s fees.

 

		9.	Use of MJFF Brand

 

You agree to
abide by the following policy regarding use of MJFF’s name, logo, marks, trade dress, image, and likeness of Michael J.
Fox, its founder (collectively, the “Brand”). MJFF prohibits any use of the MJFF Brand in any publicity efforts,
notices, releases, statements or publications without its prior written approval. All use of the Brand including, without
limitation, the name/image/likeness of Michael J. Fox shall be submitted in advance to MJFF for approval. Failure of MJFF to
approve any proposed use of the Brand within five (5) business days of its receipt of any request for approval of a proposed
use shall be deemed non-approval of the proposed use. You acknowledge that these terms are reasonable precautions to protect
the MJFF Brand and its goodwill, both of which are extremely valuable assets of MJFF. Any goodwill resulting from an approved
use of the MJFF Brand by you shall inure solely and exclusively to MJFF.

 

		10.	Publication 

 

MJFF expects that information about
the Results will be published as rapidly as possible in the open scientific literature, consistent with high standards of scientific
excellence and rigor.

 

		11.	Recognition of Funder 

 

Any publications
resulting from this Award shall include acknowledgement of the funding provided by The Michael J. Fox Foundation for Parkinson’s
Research. When publications result from work funded under this Award, you are required to update MJFF, even if such publications
occur after the end of the Award.

 

		12.	Animal or Human Subjects and Compliance with Law 

 

12.1        If your
project involves the use of animals or human subjects, you must provide a letter of approval for such use from your institution’s
regulatory assurance body prior to the initiation of funding.

 

    	 

    	 

    

 

 

 

12.2        You are solely responsible for
complying with any and all applicable laws relating to the Project.

 

		13.	Miscellaneous 

 

13.1        This Agreement including appendices constitutes the entire agreement of the parties related to its subject matter and supersedes
all prior agreements, oral or written. This Agreement may not be modified, amended or waived except by written agreement of the
parties.

 

13.2        All
notices to MJFF required or permitted by this Agreement shall be sent by email to: aharris@michaeljfox.org, unless MJFF
specifies a different person to you in writing.

 

13.3        This
Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.

 

Accepted and agreed to by:

 

	/s/ Joanne Martz	3/29/13
	Joanne Martz	 
	Chief Financial and Administrative Officer, MJFF	Date
	 	 
	/s/ Nadav Navon	 
	Nadav Navon, PhD, MBA	Date 3/4/13
	 	 
	Intec Pharma Institutional Approval:	 
	Name: GIORA CARNI	 
	Title: CEO	 
	Ph: 922-2-5864657	 
	Email: GIORA@intecpharama.com	 
	Signature:
    /s/ Giora Carni	Date 3.4.2013

 

    	 

    	 

    

 

The Michael J. Fox Foundation for Parkinson’s
Research

MJFF Research Grant 2013

Appendix A - Overview

 

Name (Last, First): Navon, Nadav

Project Title: Oral Toxicity Study in
Goettingen Pigs with 30-Day Recovery (GLP

 

	Summary of Totals	 	Total Costs ($US)	 	 	Total Director Costs ($US)	 	 	Total Indirect Cost ($US)	 
	Total Administrative Costs (from Planning Phase)	 	$	3,379.20	 	 	$	3,072.00	 	 	$	307.20	 
	Total Execution Phase (Months 4-12)	 	$	701,100.05	 	 	$	637,363.68	 	 	$	63,736.37	 
	Total Execution Phase (Months 13-24)	 	 	 	 	 	 	 	 	 	 	 	 
	Total Execution Phase (Months 25-36)	 	 	 	 	 	 	 	 	 	 	 	 
	TOTAL PROJECT BUDGET	 	$	704,479.25	 	 	$	640,435.68	 	 	$	64,043.57	 

 

Note: Totals in the grey section above will pre-populate based
on the completion of additional worksheets. Your completion of this section is not required.

 

Please
specify how much each patient visit will cost (list any details factored into the costs     NA

 

	Details	 	Costs in US $	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	Cost per patient visit	 	 	0	 

 

List the number of patient visits expected throughout the duration
of the trial.       NA

 

	 	 	Year 1	 	 	Year 2	 	 	Year 3	 	 	Total	 
	Number of Patient Visits	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0	 
	Cost of Patient Visits Per Year	 	 	0	 	 	 	0	 	 	 	0	 	 	 	0	 

 

    	 

    	 

    

 

The Michael J. Fox Foundation for Parkinson’s
Research

MJFF Research Grant 2013

Appendix A - Planning Phase (Months 1-3)

 

Name (Last, First): Navon, Nadav

Project Title: Oral Toxicity Study in Goettingen
Pigs with 30-Day Recovery (GLP

 

	Total Planning Phase Costs:	 	$	3,379.20	 
	Direct Costs	 	$	3,072.00	 
	Indirect Costs:	 	$	307.20	 

 

PERSONNEL

 

	Name	 	Role	 	% Effort	 	 	Base Salary	 	 	Salary Requested	 	 	Fringe Benefits	 	 	Total Requested	 
		 	Principal Investigator	 	 	2	%	 	$	120,000.00	 	 	$	2,400.00	 	 	$	672.00	 	 	$	3,072.00	 
	 	 	 	 	 	0	%	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 
	 	 	 	 	 	0	%	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 
	 	 	 	 	 	0	%	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 
	 	 	 	 	 	0	%	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 
	 	 	 	 	 	0	%	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	3,072.00	 

 

	Other ORB submission, database set up, etc
	Description	 	Total Requested	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	$	      	 
	 	 	 	 	 
	Direct Costs:	 	$	3,072.00	 
	Indirect Costs (10%):	 	$	307.20	 
	 	 	 	 	 
	Total Expenditures:	 	$	3,379.20	 

 

 

    	 

    	 

    

 

The
Michael J. Fox Foundation for Parkinson’s Research

MJFF Research
Grant 2013

Appendix
A - Execution Phase (Months 4-12)

 

Name (Last, First): Navon, Nadav

Project Title: Oral Toxicity Study in Goettingen
Pigs with 30-Day Recovery (GLP

 

	Total Grant Amount:	 	$	701,100.04	 
	Total Direct Costs	 	$	637,363.68	 
	Total Indirect Coots:	 	$	63,736.37	 

 

	PERSONNEL	 	 
	Name	 	Role	 	%
    Effort	 	 	Base
    Salary	 	 	Salary
    Requested	 	 	Fringe
    Benefits	 	 	Total
    Requested	 	Fixed vs. Per Patient Costs
		 	Principal Investigator	 	 	8	%	 	$	120,000.00	 	 	$	9,600.00	 	 	$	2,688.00	 	 	$	12,288.00	 	 
	 	 	 	 	 	0	%	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 
	 	 	 	 	 	0	%	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 
	 	 	 	 	 	0	%	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 
	 	 	 	 	 	0	%	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 
	 	 	 	 	 	0	%	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	12,288.00	 	 

 

	SUPPLIES,
    DATA MGMT, PATTENT VISITS (please itemize)	 	 
	Item	 	Unit
    Cost	 	 	#
    Units	 	 	Total
    Requested	 	Fixed va. Per Patient Costs
	Calvert Labs	 	$	583,400.00	 	 		1	 	 	$	583,400.00	 	 
	 	 			 	 			 				 	 
	ANALYST RESEARCH LABORATORIES LTD	 	$	41,675.68	 	 		1	 	 	$	41,675.68	 	 
	 	 	 	 	 	 			 	 	$	-	 	 
	 	 			 	 			 	 	$	-	 	 
	 	 			 	 			 	 	$	-	 	 
	 	 	 	 	 	 	 	 	 	 	$	625,075.68	 	 

	Direct Costs:	 	$	637,363.68	 	 
	Indirect Costs (10%):	 	$	63,736.37	 	 
	 	 	 	 	 	 
	Total Expenditures:	 	$	701,100.04	 	 

 

	Total Fixed Costs	 	 	 	 
	Total Per Patient Costs	 	 	 	 
	Total Months 4-12 Costs	 	 	 	 

 

    	 

    	 

    

 

 

 

Nadav Navon, PhD, MBA- MJFF Award Agreement

Appendix B - Project Payment Schedule & Milestones

 

The Michael J. Fox Foundation for Parkinson’s Research

Levodapa Delivery
- MJFF Research Grant 2013

 

Principal Investigator: Nadav Navon, PhD;

Project Title: Toxicity Study in Goettingen Pigs
with 30-Day Recovery (GLP)

 

Project Deliverables:
To evaluate in Goettingen Pigs the toxicity of Accordion Pills, containing CD/LD vs. placebo control or Sinemet, when administered
orally, by capsule, two or three times daily for 180 consecutive days, followed by one month of recovery. The study will include
thorough, focused examination of the entire gastrointestinal tract at necropsy with particular attention to the presence of residual
administered product-associated material. 

 

	Description	 	Milestones 
 (required for next payment)	 	Amount	 	 	Payment Timing
	Months 0-3 Milestones	 	•   Obtain IACUC permission and send copy to MJFF

                                             •   Send final protocol to MJFF

                                             •   Purchase 48 Goettingen Pigs
	 	$	230,000	 	 	Payable within 30 days following full execution of Award
	 	 	 	 	 	 	 	 	 
	Months 4-6 Milestones	 	•   Begin experiment (4 groups of 12 pigs each, as per protocol)

                                                                             •   Participate in follow-up call and communicate progress
                                                                             report to MJFF
	 	$	230,000	 	 	Payments will be issued based on progress reports provided to MJFF by
    Awardee. Reports will indicate progress against milestones.
	 	 	 	 	 	 	 	 	 
	Months 7-9 Milestones for Execution Phase	 	•   Conclude study

                                 •   Euthanize 3 animals/sex/group to assess presence of
                                 residual administered product associated material.

                                 •   Send final report to MJFF
	 	$	244,479.25	 	 	Payments will be issued based on progress reports provided to MJFF by
    Awardee. Reports will indicate progress against milestones.
	 	 	 	 	 	 	 	 	 
	 	 	Total Project:	 	 	 	 	 	$704,479.25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]